aspirin and Edema-Proteinuria-Hypertension Gestosis studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"To study the effect of aspirin in the prevention of pre-eclampsia in high-risk women."	10.27	Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. ( Hämäläinen, E; Kajantie, E; Laivuori, H; Pesonen, AK; Räikkönen, K; Taipale, P; Vainio, M; Villa, PM, 2013)
"The APPEC study is a large-population randomized controlled trial in China evaluating the role of low-dose aspirin prophylactic treatment for pre-eclampsia."	9.69	Low-dose aspirin in the prevention of pre-eclampsia in China: postpartum hemorrhage in subgroups of women according to their characteristics and potential bleeding risk. ( Chen, J; Huai, J; Li, B; Lin, L; Yang, H; Zhu, Y, 2023)
"The mechanism by which aspirin prevents pre-eclampsia is poorly understood, and its effects on biomarkers throughout pregnancy are unknown."	9.69	ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine artery pulsatility index trajectories in pregnancy. ( Nicolaides, KH; O'Gorman, N; Poon, LC; Rolnik, DL; Syngelaki, A; Wright, D, 2023)
"These findings suggest that individuals with twin pregnancies, a history of preeclampsia, or hypertension may not benefit from aspirin to the same extent as those with other complications such as obesity or diabetes."	9.69	Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. ( Corsi, DJ; Dagvadorj, A; Dingwall-Harvey, ALJ; El-Chaár, D; Gaudet, LM; Guo, Y; McLean, C; Muldoon, KA; Rennicks White, R; Rybak, N; Walker, MC; Wen, SW, 2023)
"The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin."	9.69	The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023)
"Daily aspirin, started in the first trimester of pregnancy, is commonly used for the prevention of preeclampsia and fetal growth restriction in multiple gestation."	9.51	Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial. ( Boutin, A; Bujold, E; Camiré, B; Carpentier, C; Guerby, P; Tapp, S, 2022)
"Evidence has shown significant benefits of aspirin for preventing pre-eclampsia."	9.41	Prevention of pre-eclampsia with aspirin: A systematic review of guidelines and evaluation of the quality of recommendation evidence. ( Ali, R; McDonald, SD; Morfaw, F; Ninan, K, 2023)
"This systematic review and meta-analysis investigated whether the use of low-dose aspirin during pregnancy by women with chronic hypertension reduces the odds of superimposed preeclampsia and poor perinatal outcomes."	9.41	Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. ( Giorgione, V; Richards, EMF; Stevens, O; Thilaganathan, B, 2023)
" The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage."	9.41	Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023)
"To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs."	9.41	Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023)
"This study aimed to compare 2 aspirin dosage regimens for the prevention of preterm preeclampsia (PE): 75 to 81 mg vs 150 to 162 mg taken daily starting in the first trimester of pregnancy."	9.41	Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. ( Bujold, E; Foisy, MA; Ghesquiere, L; Guerby, P; Kumar, N; Marchant, I; Roberge, S; Zare, M, 2023)
" The aim of this narrative review is to investigate the role of blood pressure (BP) monitoring, physical activity, and prophylactic aspirin to reduce the prevalence of preeclampsia and to improve pregnancy outcome in women with preexisting diabetes."	9.41	Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin. ( Damm, P; Do, NC; Mathiesen, ER; Nørgaard, SK; Ringholm, L; Vestgaard, M, 2023)
"Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth."	9.41	Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023)
"To examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre-eclampsia (PE)-specific biomarkers and estimated-risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis."	9.41	ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. ( Martinez-Portilla, RJ; Poon, LC; Rolnik, DL; Shen, L, 2021)
" Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation."	9.34	Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. ( Achieng, E; Bose, CL; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Miodovnik, M; Moore, J; Mwapule, A; Mwenechanya, M; Nolen, TL; Nyongesa, P; Okitawutshu, J; Patel, A; Saleem, S; Silver, R; Somannavar, M; Tshefu, A; Zehra, F, 2020)
"To evaluate the preventive effects of low-dose aspirin on the incidence of preeclampsia and pregnancy outcomes of women at high-risk for preeclampsia."	9.34	Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes: A randomized controlled trial from Shanghai, China. ( Gu, W; Hou, YY; Huang, HF; Lin, J; Lin, N; Shang, J; Song, MF; Zeng, WJ, 2020)
" The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy."	9.34	The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020)
"We observed no significant difference in UtA-PI between the two doses of aspirin, but we observed low rates of fetal growth restriction and preterm and early-onset preeclampsia (all less than 5%)."	9.34	A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on Midtrimester Uterine Artery Pulsatility Index in Women with a History of Preeclampsia. ( Bujold, E; Côté, S; Ferreira, E; Girard, M; Guerby, P; Leclair, G; Roberge, S; Tapp, S, 2020)
"This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines."	9.34	Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020)
"This article evaluates the effect of low-dose aspirin on uterine artery (UtA) Doppler, placental volume, and vascularization flow indices in low-risk pregnancy."	9.30	The Impact of Aspirin on Ultrasound Markers of Uteroplacental Flow in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Breathnach, F; Cody, F; Cotter, A; Daly, S; Dicker, P; Dornan, S; Higgins, J; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Morrison, JJ; Mulcahy, C; Tully, E, 2019)
"To assess the effect of aspirin use in low-risk pregnancy on: (1) pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) fetal growth parameters; and (4) placental histopathology."	9.30	Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Clarke, P; Culliton, M; Downey, P; Fitzgerald, D; Maguire, OC; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Mooney, EE; Mulcahy, C; Tully, E, 2019)
"There is a reduction in the total drug metabolite concentration of aspirin in pregnancy, and therefore a dose adjustment is potentially required in pregnant women."	9.30	A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. ( Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)
"Our objective was to determine whether low-dose aspirin reduces the rate of spontaneous preterm birth in nulliparous women without medical comorbidities."	9.27	Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. ( Andrikopoulou, M; Gyamfi-Bannerman, C; Handal-Orefice, R; Purisch, SE, 2018)
" Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin."	9.24	A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017)
" It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia."	9.24	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Gizurarson, S; Janga, D; Jani, JC; Maclagan, K; Meiri, H; Molina, FS; Nicolaides, KH; O'Gorman, N; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tenenbaum-Gavish, K; Wright, D, 2017)
"There is a lack of evidence for pre-eclampsia prophylaxis with aspirin in women with pre-existing diabetes mellitus (DM)."	9.22	Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review. ( Alahakoon, TI; Cheung, NW; Haider, R; Jesudason, S; Lee, VW; Nolan, CJ; Padmanabhan, S; Peek, M; Simmons, D; Zen, M, 2022)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."	9.22	Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The objective of this study is to determine whether low-dose aspirin (LDA) reduced the rate of preterm birth (PTB) in a cohort of women at high risk for preeclampsia."	9.22	The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. ( Allshouse, AA; Heyborne, KD; Jessel, RH, 2016)
"The objective of the study is to evaluate low-dose aspirin (LDA) for pre-eclampsia prevention in twin gestations with elevated maternal serum human chorionic gonadotropin (hCG)."	9.22	Low-dose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin. ( Allshouse, AA; Euser, AG; Heyborne, KD; Metz, TD, 2016)
"We propose a three armed multi-center open-labeled randomized control trial of; (i) routine LDA, (ii) no aspirin, and (iii) LDA on the basis of a positive first trimester pre-eclampsia screening test."	9.22	An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. ( Breathnach, F; Culliton, M; Dicker, P; Downey, P; Malone, FD; McAuliffe, FM; McCormack, D; McParland, P; Mone, F; Mulcahy, C; Stanton, A; Tully, E, 2016)
"The aim of this study is to analyze the effect of 100 mg/d regular oral intake of aspirin during pregnancy on high-risk pregnancy-induced hypertension syndrome patients."	9.22	Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016)
"Late timing of intervention and maternal obesity are potential explanations for the modest effect of aspirin for preeclampsia prevention."	9.20	Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? ( Abramovici, AR; Biggio, JR; Cantu, JA; Edwards, RK; Jauk, VR; Owen, J; Tita, AT, 2015)
"Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort."	9.20	Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015)
"To estimate the effect of early administration of aspirin on the prevention of pre-eclampsia in high-risk women."	9.20	Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. ( Goetzinger, KR; Odibo, AO; Odibo, L; Tuuli, MG, 2015)
"To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2."	9.19	Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014)
"Adding low-molecular-weight heparin (LMWH) to aspirin at < 12 weeks gestation reduces the recurrence of HD in women with previous early-onset HD (pre-eclampsia, hemolysis, elevated liver enzymes and low platelets [HELLP] syndrome and eclampsia) and/or SGA, in the context of inheritable thrombophilia without antiphospholipid antibodies."	9.16	Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. ( Bezemer, PD; de Vries, JI; Hague, WM; Joosten, JH; van Pampus, MG, 2012)
"Low-dose aspirin therapy could improve remodelling of maternal spiral arteries during early placentation and prevent subsequent pregnancy-related hypertensive disorders."	9.14	Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010)
"Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure."	9.12	Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021)
" We included randomized controlled trials reporting on health-related outcomes in children (aged > 28 days) exposed to aspirin versus placebo or no treatment during pregnancy."	9.12	Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. ( de Boer, MA; Finken, MJJ; Ket, JCF; Landman, AJEMC; Leemhuis, AG; Oudijk, MA; Painter, RC; van 't Hooft, J; van Limburg Stirum, EVJ, 2021)
"The use of low dose aspirin (LDA) has become routine in prenatal care for a variety of diagnoses, most importantly in women with a history of preeclampsia and associated poor pregnancy outcomes."	9.12	Low-dose aspirin in pregnancy: who? when? how much? and why? ( Dom, AM; Mather, AR; Thorburg, LL, 2021)
" Aspirin prophylaxis substantially lowered the risk of pre-eclampsia, preterm birth, perinatal mortality, and intrauterine growth retardation without elevated bleeding risks."	9.12	Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis. ( Choi, YJ; Shin, S, 2021)
"To verify whether prophylaxis with low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA) could positively affect pregnancy outcome in women with a history of severe preeclampsia."	9.12	Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. ( Alessandro, C; Gabriella, F; Giancarlo, P; Giorgia, S; Maria Clara, D; Sergio, F, 2006)
"To determine if aspirin (ASA) therapy reduces the incidence of pre-eclampsia in women at high risk of this condition."	9.11	A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia. ( Acaia, B; Chiaffarino, F; Del Giudice, A; Facchinetti, F; Marozio, L; Ossola, W; Paladini, D; Parazzini, F, 2004)
"To reduce the incidence of pre-eclampsia in nulliparous women, in accordance with the suggestion of a recent meta-analysis that low dose aspirin might decrease this incidence by more than half if used early enough in and at a sufficient dose during pregnancy (more than 75 mg)."	9.10	Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). ( Biausque, S; Breart, G; Churlet, A; Goeusse, P; Lequien, P; Marquis, P; Parmentier, D; Puech, F; Subtil, D; Uzan, S, 2003)
"In pregnancies with impaired placentation, as demonstrated by increased impedance to flow in the uterine arteries, the daily administration of 150 mg aspirin after 23 weeks of gestation does not prevent the subsequent development of pre-eclampsia."	9.10	Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. ( Nicolaides, KH; Palma Dias, R; Papageorghiou, AT; Parra, M; Yu, CK, 2003)
"This study extends previous results on the effects of low-dose aspirin on blood pressure in pregnant women at differing risk of developing hypertension in pregnancy and who received aspirin at different times according to their rest-activity cycle."	9.09	Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. ( Alonso, I; Ayala, DE; Codesido, J; Fernández, JR; Hermida, RC; Iglesías, M; Mojón, A; Silva, I; Ucieda, R, 1999)
"To investigate the effect of low-dose, slow-release aspirin in reducing the incidence and/or severity of pregnancy complications in women identified as high risk of developing problems associated with uteroplacental insufficiency, namely pre-eclampsia or delivering a small-for-gestational age (SGA) baby."	9.09	A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. ( Aquilina, J; Campbell, S; England, P; Harrington, K; Kurdi, W, 2000)
"Daily administration of low-dose aspirin during the second and third trimesters of pregnancy does not alter uteroplacental or fetoplacental hemodynamics and does not cause moderate or severe constriction of the ductus arteriosus."	9.09	Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. ( Erdmann, M; Grab, D; Kreienberg, R; Lang, D; Muche, R; Oberhoffer, R; Paulus, WE; Terinde, R, 2000)
" The angiotensin II-sensitive women were randomized to 60 mg of aspirin or placebo as a subset of a large multicenter, randomized, controlled trial of low-dose aspirin therapy in pregnancy."	9.08	The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. ( Buckley, D; de Swiet, M; Kissane, J; Kyle, PM; Redman, CW, 1995)
" Whether patients were assigned to aspirin or placebo, birth weight was significantly greater in women who had a twofold or greater reduction in maternal serum thromboxane B2 levels."	9.08	Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. ( Copper, RL; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995)
"Our purpose was to determine the frequency and safety of the use of epidural anesthesia and the correlation between bleeding time and maternal-neonatal bleeding complications in a group of pregnant women who participated in a multicenter trial of low-dose aspirin in pregnancy."	9.08	Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. ( Caritis, SN; McNellis, D; Shaw, K; Sibai, BM; Thom, E, 1995)
"To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation."	9.08	Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995)
"To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia."	9.08	ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996)
"To assess the effect of low dose aspirin on severe pre-eclampsia when given to women identified as high risk by abnormal uterine artery Doppler ultrasound."	9.08	Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. ( Bower, SJ; Campbell, S; Harrington, KF; McGirr, C; Schuchter, K, 1996)
"To analyze determinants of the risk of pregnancy-induced hypertension (PIH) with or without proteinuria, we compared characteristics of women enrolled in the Italian Study of Aspirin in Pregnancy who developed PIH and those who did not."	9.08	Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. ( Benedetto, C; Bortolus, R; Chatenoud, L; Marozio, L; Parazzini, F; Restelli, S; Ricci, E, 1996)
"There is evidence that aspirin in low doses favourably influences the course and outcome of pregnancy in women at risk of developing pregnancy-induced hypertension."	9.08	Low dose aspirin in prevention of pregnancy-induced hypertension in primigravidae at the Muhimbili Medical Center, Dar es Salaam. ( Mgaya, HN; Ramaiya, C, 1995)
"The use of low-dose aspirin for the prevention and treatment of pre-eclampsia and intrauterine growth restriction has been studied extensively during the last 10 years."	9.08	Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. ( Bar, J; Fisch, B; Hod, M; Kaplan, B; Meizner, I; Pardo, J; Rabinerson, D, 1997)
"We found an association between the addition of ketanserin to aspirin and a decrease in the number of cases of pre-eclampsia and severe hypertension, as well as improved pregnancy outcome among patients with mild to moderate midtrimester hypertension."	9.08	Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. ( Odendaal, HJ; Steyn, DW, 1997)
"To determine whether low-dose aspirin reduces the incidence of pre-eclampsia, reduces perinatal mortality and improves birth weights in pregnant women considered at high risk of developing pre-eclampsia."	9.08	A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. ( Byaruhanga, RN; Chipato, T; Rusakaniko, S, 1998)
"The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings."	9.08	Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998)
"To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation."	9.08	A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998)
"Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders."	9.07	Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993)
"To study the effect of daily treatment with 50 mg of aspirin (ASA) on the hypertensive pregnancy complications and on the production prostacyclin (PGI2) and thromboxane A2 (TxA2) in high risk pregnant women and their infants."	9.07	Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. ( Hartikainen-Sorri, AL; Hiilesmaa, V; Lumme, R; Viinikka, L; Ylikorkala, O, 1993)
"Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia."	9.07	Low-dose aspirin therapy to prevent preeclampsia. ( Copper, RL; Cutter, GR; DuBard, MB; Goldenberg, RL; Hauth, JC; Parker, CR; Philips, JB, 1993)
"A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia."	9.07	Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991)
"The effect of low doses of aspirin on women with mild pregnancy-induced hypertension was investigated by means of a prospective, randomized, double-blind trial."	9.06	Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension. ( Barkai, G; Ben-Baruch, G; Mashiach, S; Schiff, E, 1990)
"We carried out a prospective, randomized, double-blind, placebo-controlled study to investigate the capacity of aspirin to prevent pregnancy-induced hypertension and to alter prostaglandin metabolism."	9.06	The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. ( Barkai, G; Ben-Baruch, G; Blankstein, J; Goldenberg, M; Peleg, E; Rosenthal, T; Ruppin, E; Schiff, E; Tamarkin, M; Yahal, I, 1989)
"The possibility of preventing pregnancy-induced hypertension (PIH) and pre-eclampsia in primigravidae by suppressing production of thromboxane A2 with low-dose aspirin was investigated in a randomised, placebo-controlled, double-blind trial."	9.06	Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. ( Dekker, GA; Makovitz, JW; Rotmans, P; Wallenburg, HC, 1986)
"Since the 1970s, we have known that aspirin can reduce the risk of pre-eclampsia."	9.05	Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition? ( Danser, AHJ; Mirabito Colafella, KM; Neuman, RI; Versmissen, J; Visser, W, 2020)
"We performed a systematic review and meta-analysis to evaluate the effect of low-dose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy."	9.05	Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? ( Chaemsaithong, P; Cuenca-Gomez, D; Gil, MM; Plana, MN; Poon, LC, 2020)
"For the past decades, growing attention has been given to aspirin use during pregnancy."	9.05	Aspirin for prevention of preeclampsia and fetal growth restriction. ( Guerby, P; Hamdi, SM; Loussert, L; Parant, O; Vayssiere, C; Vidal, F, 2020)
"Aspirin and heparin are widely used as preventive strategy to reduce the high risk of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL)."	9.05	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. ( Goddijn, M; Hamulyák, EN; Marijnen, MC; Middeldorp, S; Scheres, LJ, 2020)
"Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration."	9.05	Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020)
" Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes."	9.05	The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020)
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."	9.01	[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"We performed a systematic review and metaanalysis that evaluated the prophylactic effect of aspirin during pregnancy."	8.98	Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018)
"We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug."	8.98	Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018)
"To assess the accuracy of the National Institute of Health and Care Excellence (NICE) and United States Preventive Services Task Force (USPSTF) guidelines for predicting pre-eclampsia in pregnancy to guide aspirin prophylaxis."	8.98	Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis. ( Al-Rubaie, ZTA; Askie, LM; Hudson, HM; Jenkins, G; Lord, SJ; Ray, JG, 2018)
"We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction."	8.95	The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. ( Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017)
"To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone."	8.93	Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016)
"To estimate the impact of adding low-molecular-weight heparin (LMWH) or unfractionated heparin to low-dose aspirin started ≤ 16 weeks' gestation on the prevalence of pre-eclampsia (PE) and the delivery of a small-for-gestational-age (SGA) neonate."	8.93	Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. ( Bujold, E; Bureau, M; Côté, S; Demers, S; Nicolaides, KH; Roberge, S, 2016)
" Individual patient data meta-analysis indicates that low-dose aspirin causes a 10% risk reduction in pre-eclampsia for women at high individual risk."	8.93	Low dose aspirin and pregnancy: how important is aspirin resistance? ( Alfirevic, A; Alfirevic, Z; Navaratnam, K, 2016)
"Low-dose aspirin (LDA) is thought to prevent preeclampsia in high-risk pregnancy, but it is not universally used out of concern for its efficacy and safety."	8.91	Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. ( Deng, CY; Huang, GQ; Li, JK; Wang, XD; Xu, TT; Zhou, F, 2015)
"In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight."	8.91	[Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015)
"The aim of this study is to review literature about the efficacy of low dose aspirin (LDA) and vitamins C/E (VCE) to prevent pre-eclampsia in women at high and low risk."	8.87	Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. ( Mullin, PM; Rossi, AC, 2011)
"To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)."	8.86	Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010)
"Investigate cost-effectiveness of first trimester pre-eclampsia screening using the Fetal Medicine Foundation (FMF) algorithm and targeted aspirin prophylaxis in comparison with standard care."	8.84	First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study. ( Ammari, C; Casagrandi, D; Hillman, S; Napolitano, R; Nzelu, D; Palmer, T; Pandya, P; Stott, D, 2024)
"To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality."	8.79	Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995)
"Our results demonstrated that the combination of quercetin and aspirin exerted significantly stronger effects than aspirin alone on decreasing systolic blood pressure and proteinuria, reducing pro-inflammatory cytokine production, and inhibiting M1-type decidual macrophages polarization in an LPS-induced rat model of preeclampsia."	8.31	Natural Flavonoid Quercetin Enhances the Anti-inflammatory Effects of Aspirin in a Preeclampsia-like Rat Model Induced by Lipopolysaccharide. ( Chen, D; Ding, J; Liu, A; Yang, S, 2023)
"Treatment with curcumin and aspirin combination significantly reduced the systolic blood pressure and proteinuria in the PE rats."	8.31	Combining curcumin and aspirin ameliorates preeclampsia-like symptoms by inhibiting the placental TLR4/NF-κB signaling pathway in rats. ( Feng, Y; Hou, X; Ju, Y; Wang, Y; Yang, M; Yang, Y; Zhang, X; Zhu, X, 2023)
"The purpose of this study was to assess obstetrician-gynecologist utilization of low-dose aspirin for women at increased risk for hypertensive disorders of pregnancy using guidelines developed by the American College of Obstetricians and Gynecologists and supported by the United States Preventive Services Task Force."	8.31	Relationship between risk factor profile and prescription of low-dose aspirin for preeclampsia prevention. ( Holmgren, C; Phelps, AJD, 2023)
"Many clinical trials have reported that low-dose aspirin decreases the risk of pre-eclampsia in women with prior pre-eclampsia."	8.31	Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study. ( Blacher, J; Deneux-Tharaux, C; Gabet, A; Grave, C; Kretz, S; Lailler, G; Olie, V; Plu-Bureau, G; Regnault, N; Tsatsaris, V, 2023)
"To investigate the effectiveness of low-dose aspirin (LDA) in the prevention of pre-eclampsia (PE) among otherwise low-risk twin gestations."	8.31	Reconsidering the effectiveness of low-dose aspirin in prevention of pre-eclampsia among otherwise low risk twin gestations: A historical cohort study. ( Brantz, Y; Farhi, A; Lerner-Geva, L; Maymon, D; Mazaki-Tovi, S; Meyer, R; Toussia-Cohen, S; Tsur, A; Yinon, Y; Zaslavsky-Paltiel, I, 2023)
"Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia."	8.31	Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. ( Combs, CA; Kumar, NR; Morgan, JL, 2023)
"To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)."	8.31	The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023)
"Adherence to low-dose aspirin is key in preventing pre-eclampsia."	8.31	Let's talk aspirin: A survey of barriers and facilitators faced by midwives when engaging in conversations about aspirin with women at risk of pre-eclampsia. ( Araújo-Soares, V; Farnworth, A; Hiu, S; McParlin, C; Smith, V; Vinogradov, R, 2023)
"Current guidelines recommend low-dose aspirin for preeclampsia prophylaxis in all women with pregestational (type one and type two) diabetes mellitus."	8.12	Associations between aspirin prophylaxis and fetal growth and preeclampsia in women with pregestational diabetes. ( Graham, DF; Shrestha Khatri, N; White, SW, 2022)
"To compare the predictive performance for preterm-pre-eclampsia (PE) in first-trimester screening by serum placental growth factor (PlGF) versus pregnancy associated plasma protein-A (PAPP-A), in combination with maternal risk factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI), after adjustment for the effect of aspirin in women receiving this treatment."	8.12	Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. ( Nicolaides, KH; O'Gorman, N; Syngelaki, A; Tan, MY; Wright, D, 2022)
"To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk."	8.12	Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022)
"To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy."	8.12	Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022)
"Clinical studies suggest that early pregnancy is the critical window for the prevention of preeclampsia by low-dose aspirin (LDA)."	8.12	Low-dose aspirin prevents LPS-induced preeclampsia-like phenotype via AQP-1 and the MAPK/ERK 1/2 pathway. ( Feng, L; Jing, S; Xie, H; Zhang, H; Zhang, J, 2022)
"The use of 100 mg of aspirin a day before the 20th week of pregnancy in high risk pregnant patients decreased the risk of developing PREEC, regardless the age and risk factors."	8.12	[Use of aspirin 100 mg / day to prevent Preeclampsia, in high risk pregnancies, in a cohort from Argentina]. ( Espeche, WG; Minetto, J; Salazar, MR, 2022)
"Aspirin is a common drug for the treatment of pre-eclampsia."	8.12	Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome. ( Chen, D; Ding, J; Song, L; Yang, S; Zhang, J; Zhang, Y, 2022)
"To determine the impact of low-dose aspirin (81 mg) on markers of maternal inflammation and placental function."	8.12	The impact of low-dose aspirin on markers of inflammation and placental function: an ancillary study of the ASPIRIN trial. ( Araganji, R; Goudar, SS; Hoffman, MK; Kavi, A; Somannavar, MS; Vernekar, SS, 2022)
"The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia."	8.02	Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021)
" Digital tools such as the MyHealthyPregnancy app might offer an opportunity to improve identification of patients at risk for preeclampsia and communication with these patients about aspirin use."	8.02	Use of a Smartphone App to Explore Potential Underuse of Prophylactic Aspirin for Preeclampsia. ( Bernard, M; Davis, AL; Hayani, L; Krishnamurti, T; Rodriguez, S; Simhan, HN, 2021)
" Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy."	8.02	Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021)
"Aspirin is widely used to prevent pregnancy related vascular disorders such as preeclampsia (PE), intrauterine growth restriction and maternal disorders."	8.02	Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta analysis. ( Dorsamy, V; Khaliq, OP; Mkhize, PZ; Moodley, J; Phoswa, WN, 2021)
"Decision tree analysis was created using R software to evaluate four approaches to aspirin prophylaxis in the United States: no aspirin, United States Preventive Service Task Force (USPSTF) with Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) hypertension guidelines, USPSTF with ACC/AHA hypertension guidelines, as well as universal aspirin prophylaxis."	8.02	The Impact of the New Hypertension Guidelines to Low-Dose Aspirin Prophylaxis Eligibility for the Prevention of Preeclampsia: A Cost-Benefit Analysis. ( Balasooriya, MM; Boscia, AL; Dalkiran, E; Putra, M; Sokol, RJ, 2021)
"To evaluate the effects of low-molecular-weight heparin (LMWH) combined with low-dose aspirin (LDA) in pregnant women with a history of pregnancy-related hypertensive disorders."	8.02	Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study. ( Chen, Y; Shen, F; Wang, J; Yang, W; Zhang, Y; Zhou, J, 2021)
"Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)."	8.02	Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021)
"Aspirin is routinely prescribed in high-risk pregnancies to prevent pre-eclampsia; however, there is a paucity of data in women with pre-existing diabetes."	8.02	Aspirin and pre-eclampsia prevention in women with pre-existing diabetes: a retrospective study. ( Athayde, N; Cheung, NW; Inglis, E; Lah, S; Lee, V; Padmanabhan, S, 2021)
"The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD)."	8.02	Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study : This is the study for kidney and pregnancy... ( Chen, Q; Chen, S; He, Y; Wang, M; Yang, H; Zhao, M, 2021)
"Despite being key to reducing the occurrence of pre-eclampsia in high-risk women, adherence to aspirin prophylaxis is low, reflecting multifactorial challenges faced by pregnant women."	8.02	Informational needs related to aspirin prophylactic therapy amongst pregnant women at risk of preeclampsia - A qualitative study. ( Araujo-Soares, V; Robson, SC; Smith, VJ; Vinogradov, R, 2021)
"Plasma from women with pre-eclampsia induced TBARS and nitrotyrosine production on endothelial and U937 cells."	7.96	Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia. ( Alvarez, AM; Cadavid J, AP; Gil-Villa, AM; Rojas-López, M; Velásquez-Berrío, M, 2020)
"The study is aimed at understanding the factors, from the women's perspective, that influenced adherence with prophylactic aspirin in their pregnancy."	7.96	Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis. ( Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Liamputtong, P; Makris, A; Mengesha, Z; Notaras, S; Shanmugalingam, R, 2020)
"To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings."	7.96	Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020)
"To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo."	7.96	Maternal cardiac function in women at high risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study. ( Bisquera, A; Jara, PG; Kametas, NA; Ling, HZ; Nicolaides, KH; Poon, LC, 2020)
"(1) To evaluate the rates of implementation of the 2016 American College of Obstetricians and Gynecologists guideline over time; and (2) to evaluate the effectiveness of aspirin for the prevention of superimposed preeclampsia and other adverse maternal and neonatal outcomes in women with chronic hypertension before and after this guideline."	7.96	Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension. ( Banala, C; Berghella, V; Boelig, RC; Cruz, Y; Moreno, S; Roman, A; Saccone, G; Schoen, CN, 2020)
"A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)."	7.96	Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020)
"We designed a decision analysis to compare preeclampsia-related costs and effects of four strategies for aspirin use in pregnancy initiated before 16 weeks of gestation to prevent preeclampsia."	7.91	Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. ( Grobman, W; Mallampati, D; Rouse, DJ; Werner, EF, 2019)
"Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders."	7.91	Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019)
"Women with lupus have an increased risk of preeclampsia and preterm birth, and aspirin 81 mg/day is recommended as a preventative measure for preeclampsia."	7.91	Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. ( Clowse, MEB; Eudy, AM; Myers, RA; Voora, D, 2019)
"To study women who initiated aspirin in the first trimester for high risk of pre-eclampsia, and compare blood-pressure trends throughout pregnancy between those with normal outcome and those who subsequently developed pre-eclampsia."	7.88	Maternal blood-pressure trends throughout pregnancy and development of pre-eclampsia in women receiving first-trimester aspirin prophylaxis. ( Baschat, AA; Blitzer, MG; Block-Abraham, D; Dewberry, D; Miller, JL; Seravalli, V, 2018)
"Low-dose aspirin is recommended for prevention of pre-eclampsia in high-risk pregnant women."	7.88	Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. ( Alfirevic, A; Alfirevic, Z; Jorgensen, A; Navaratnam, K, 2018)
"We sought to examine the effect of prophylactic use of aspirin during pregnancy in women at high risk of preeclampsia on length of stay in the neonatal intensive care unit."	7.88	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. ( de Alvarado, M; de Paco Matallana, C; Jani, JC; Machuca, M; Mastrodima, S; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tan, MY; Wright, D, 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."	7.88	ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."	7.88	ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Aspirin use during pregnancy was associated with a reduced risk of hypoxia-related placental pathology in the high-risk population [the adjusted odds ratio and 95% confidence interval in the 1st, 2nd, and 3rd trimesters: 0."	7.88	Aspirin use during pregnancy and hypoxia-related placental pathology. ( Chen, C; Chen, Y; Feng, L; Ye, J; Ye, W; Zhang, J; Zhu, J; Zhu, X, 2018)
"The beneficial effect of aspirin in the prevention of preterm preeclampsia may not apply in pregnancies with chronic hypertension."	7.85	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. ( Akolekar, R; De Stefani, L; Delgado, JL; Evangelinakis, N; Gonzalez-Vanegas, O; Jani, JC; Leipold, G; Nicolaides, KH; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tsokaki, T; Wright, D, 2017)
"To examine the effect of a combination of screening and treatment with low-dose aspirin on the prevalence of early-onset pre-eclampsia (PE)."	7.81	Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. ( Hyett, J; Leung, C; Ogle, R; Park, F; Pelosi, M; Puddephatt, R; Rawashdeh, H; Russo, K; Saaid, R; Walter, M; Williams, P, 2015)
" Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy."	7.80	Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. ( LeFevre, ML, 2014)
"Aspirin treatment compared with untreated control groups led to a significant reduction of preeclampsia in 5 small-scale studies."	7.78	-Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies-. ( Lippert, TH; Mück, AO, 1996)
"In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")."	7.77	Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011)
"Verify that resistance to aspirin may have an impact on pregnancy and neonatal outcome."	7.77	Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011)
" We present critical issues that need to be considered when evaluating and appraising test-treatment combinations, using the example of research on the uterine artery Doppler test to predict, and aspirin to prevent, pre-eclampsia."	7.76	How to interpret randomised trials of test-treatment combinations: a critical evaluation of research on uterine Doppler test to predict, and aspirin to prevent, pre-eclampsia. ( Coomarasamy, A; Fox, C; Khan, KS, 2010)
"Treatment of preeclampsia with prostacyclin appears to be contraindicated because prostacyclin is a potent systemic vasodilator and the clinical outcome of preeclamptic women infused with prostacyclin has been poor."	7.76	Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia. ( Walsh, SW, 1989)
"Two meta-analyses suggest that low-dose aspirin taken daily during pregnancy reduces the incidence of pre-eclampsia in women at risk and reduces mortality among the infants born to mothers at high risk of pre-eclampsia."	7.75	Pre-eclampsia: aspirin beneficial. ( , 2009)
"To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia."	7.74	Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007)
"To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome."	7.70	Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998)
"Despite optimism generated by earlier, smaller studies, the Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) trial showed that aspirin is not sufficiently effective to recommend its widespread use for the prevention of pre-eclampsia."	7.69	Pre-eclampsia. III: The role of aspirin in prevention. ( de Swiet, M, 1994)
"To determine if low dose aspirin therapy improves placental histology in women with a prior complicated pregnancy demonstrating uterine vascular pathology."	7.69	Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. ( Campbell, WA; Cusick, W; Ernst, L; Rodis, JF; Salafia, CM; Vintzileos, AM, 1995)
" Magnesium and dihydralazine effects in pregnancy are not related to altered release of trophoblast vasoactive compounds."	7.69	Drug actions in preeclampsia: aspirin, but not magnesium chloride or dihydralazine, differentially inhibits cultured human trophoblast release of thromboxane and prostacyclin without affecting angiotensin II, endothelin-1, or leukotriene B4 secretion. ( Cervar, M; Desoye, G; Kainer, F; Nelson, DM, 1997)
"To describe patterns of prescription in the Netherlands of low-dose aspirin in pregnancy."	7.68	Low-dose aspirin in pregnancy: changes in patterns of prescription in The Netherlands. ( Bremer, HA; Wallenburg, HC, 1993)
"To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation."	7.68	Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993)
" Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established."	7.68	[A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992)
"The incidence of preterm preeclampsia was 1."	7.30	Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023)
"The main outcome was preeclampsia or a birthweight ≤ 5th percentile."	7.11	Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial. ( Arthuis, C; Cheve, MT; Debarge, VH; Delmas, HL; Diguisto, C; Doret, M; Durin, L; Equy, V; Flandrin, A; Gallot, D; Giraudeau, B; Haddad, G; Le Gouge, A; Marchand, MS; Mares, P; Megier, P; Paumier, A; Perrotin, F; Schaub, B; Sentilhes, L; Vayssiere, C; Ville, Y; Winer, N, 2022)
"A dosage of 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation, did not reduce the incidence of preeclampsia in pregnant women with high-risk factors in China."	7.11	A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. ( Chen, D; Chen, J; Cui, S; Ding, H; Huai, J; Juan, J; Li, B; Li, G; Li, X; Lin, L; Ma, Y; Mi, Y; Qi, H; Sun, X; Yang, H; Yu, M; Zhang, H; Zhang, M; Zhang, W; Zhao, X; Zhao, Y; Zhu, Y, 2022)
"Preeclampsia is a hypertensive disorder of pregnancy affecting up to 8% of pregnancies."	7.01	Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy. ( Costantine, MM; Eid, J; Rood, KM, 2023)
"Aspirin was not found to substantially diminish the risk of incidence of preeclampsia, but it did show some beneficial effects."	7.01	Role of aspirin in the prevention of preeclampsia in previously hypertensive pregnant women: A Meta-Analysis. ( Ashraf Jahangeer, SM; Khan, AA; Mansoor, M, 2023)
"Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR)."	7.01	Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol). ( Adeyemo, TA; Afolabi, BB; Babah, OA; Ezeaka, CV; Nwaiwu, O; Odukoya, OO; Ogunnaike, BA; Oshodi, YA, 2021)
"The risk of preeclampsia was not different when comparing the aspirin and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and race groups."	6.94	Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. ( Aagaard, KM; Mendez-Figueroa, H; Sangi-Haghpeykar, H; Tolcher, MC, 2020)
"The Aspirin for Evidence-Based Preeclampsia Prevention trial data are consistent with the hypothesis that aspirin delays the gestational age at delivery with preeclampsia."	6.90	Aspirin delays the development of preeclampsia. ( Nicolaides, KH; Wright, D, 2019)
"Among women receiving placebo, preeclampsia occurred significantly more often in women with stage 1 hypertension compared with normotensive high-risk women after adjustment for maternal age and body mass index (39."	6.87	Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. ( Caritis, SN; Catov, JM; Hauspurg, A; Sutton, EF, 2018)
"When aspirin was initiated at > 16 weeks, with a dosage of < 100 mg/day aspirin, there was a lesser preventive effect (RR = 0."	6.82	The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. ( Dai, C; He, Q; Huang, X; Lee, W; Li, L; Li, R; Luo, Z; Mok, TN; Yip, KC; Zeng, W, 2022)
"Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth."	6.82	The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022)
" These inconsistencies, however, can be largely explained by a high degree of heterogeneity regarding the selection of trial participants, baseline risk of the included women, dosage of aspirin, gestational age of prophylaxis initiation, and preeclampsia definition."	6.82	Prevention of preeclampsia with aspirin. ( Nicolaides, KH; Poon, LC; Rolnik, DL, 2022)
"Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17."	6.80	Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Post, AL, 2015)
"The rate of superimposed preeclampsia was 28."	6.79	Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial. ( Atallah, AN; Kulay, L; Santos, GM; Sass, N; Souza, EV; Torloni, MR, 2014)
"In preterm preeclampsia, women assigned at random to 150 mg experienced a significant 62% reduction in risk of preterm preeclampsia (RR = 0."	6.72	Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis. ( Flyke, IP; Hennekens, CH; Hoppe, KK; Kim, K; Lasarev, M; Mukhtarova, N; Van Doorn, R, 2021)
"It was effective in reducing preterm preeclampsia, but not term preeclampsia, and patient compliance and patient weight were important variables."	6.72	The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta. ( Strauss, JF; Walsh, SW, 2021)
"Salicylic acid was detected in 1 infant only."	6.71	Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. ( Bernert, S; Leonhardt, A; Schmitz-Ziegler, G; Seyberth, HW; Watzer, B, 2003)
"The trial enrolled 139 women at risk of preeclampsia or IUGR, with abnormal uterine artery Doppler findings that included the presence of unilateral or bilateral diastolic notch, high resistance index (RI), or high pulsatility index (PI) at 14-16 weeks of gestation."	6.71	Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. ( Ebrashy, A; Ibrahim, M; Marzook, A; Yousef, D, 2005)
"Whether low-dose aspirin prevents preeclampsia is unclear."	6.69	Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998)
"Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery."	6.67	CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994)
"To assess its efficacy in preventing preeclampsia, 60 mg/day aspirin or a matching placebo was administered to women in a double-blind fashion during the second and third trimesters."	6.67	Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. ( Arheart, KL; Di Sessa, TG; Khoury, A; Moretti, ML; Pulliam, DA; Sibai, BM, 1994)
"The occurrences of IUGR and preeclampsia in the study group (7."	6.67	[Prevention of fetal growth retardation by low dose aspirin]. ( Li, WJ; Wang, ZH, 1993)
"The incidence of preeclampsia was lower in the aspirin group (69 of 1485 women [4."	6.67	Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, SN; Klebanoff, M; McNellis, D; Paul, RH; Rocco, L; Romero, R; Rosen, M; Sibai, BM; Thom, E; Witter, F, 1993)
"Chronic hypertension affects 1-5% of women of childbearing age."	6.66	Aspirin for the prevention of placenta-mediated complications in pregnant women with chronic hypertension. ( Haddad, B; Lecarpentier, E, 2020)
" Screening modalities, target population, and aspirin dosage are still a matter of debate."	6.55	Aspirin for Prevention of Preeclampsia. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2017)
"Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin."	6.55	[Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017)
"Outcomes included preeclampsia (mild and severe) and SGA neonates."	6.53	Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Outcomes included preeclampsia, severe preeclampsia, and SGA."	6.53	Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide."	6.53	Aspirin vs Heparin for the Prevention of Preeclampsia. ( Kanellopoulou, T; Katsi, V; Makris, T; Nihoyannopoulos, P; Nomikou, E; Tousoulis, D, 2016)
"Low-dose aspirin significantly reduced preeclampsia risk in both East Asians (OR = 0."	6.53	Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians:A systematic review and meta-analysis. ( Gan, J; He, H; Qi, H, 2016)
"Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality."	6.50	Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014)
"The outcomes of interest were preterm preeclampsia (delivery <37 weeks) and term preeclampsia."	6.48	Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. ( Bakthi, A; Bujold, E; Ebrashy, A; Giguère, Y; Nicolaides, K; Roberge, S; Vainio, M; Villa, P, 2012)
"The outcomes of interest were severe preeclampsia and mild preeclampsia."	6.48	Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. ( Bujold, E; Forest, JC; Giguère, Y; Nicolaides, K; Roberge, S; Tapp, S; Vaiman, D; Vainio, M; Villa, P; von Dadelszen, P; von Dadelzen, P, 2012)
"The incidence of preeclampsia was 3."	6.43	Prevention of preeclampsia with low-dose aspirin -- a systematic review and meta-analysis of the main randomized controlled trials. ( Fontes, RS; Ruano, R; Zugaib, M, 2005)
"Aspirin was also associated with a reduction in rates of spontaneous preterm birth (OR 0."	6.42	Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. ( Coomarasamy, A; Gee, H; Honest, H; Khan, KS; Papaioannou, S, 2003)
" Discrepancies seem largely related to either studying very low-risk populations, or strong differences in aspirin dosage and/or term of introduction."	6.41	[Aspirin and prevention of pre-eclampsia]. ( Beaufils, M, 2000)
"The baseline risk of preeclampsia in women with abnormal uterine artery Doppler was 16%, and the number of women needed to be treated with aspirin to prevent one case of preeclampsia was 16 (95% CI 8, 316)."	6.41	Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. ( Coomarasamy, A; Gee, H; Khan, KS; Papaioannou, S, 2001)
"On the basis of the hypothesis that preeclampsia is at least partially caused by an increase in thromboxane A2, some studies attempted to correct this pathologic condition by pharmacologic manipulation with low-dose aspirin."	6.38	Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. ( Dekker, GA; Sibai, BM, 1993)
"To study the effect of aspirin in the prevention of pre-eclampsia in high-risk women."	6.27	Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. ( Hämäläinen, E; Kajantie, E; Laivuori, H; Pesonen, AK; Räikkönen, K; Taipale, P; Vainio, M; Villa, PM, 2013)
"To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients."	5.91	Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression of ATF2. ( Guo, L; Hu, R; Liu, R; Xiao, S; Zhang, M, 2023)
" The Royal College of Obstetricians and Gynaecologists recommends 150 mg of aspirin daily, and the National Institute of Health and Care Excellence guidelines suggest risk stratification with a dosage of 75 mg for those at moderate risk of preeclampsia and 150 mg for those at high risk of preeclampsia."	5.91	Low-dose aspirin therapy for the prevention of preeclampsia: time to reconsider our recommendations? ( Abuhamad, A; Hage Diab, Y; Horgan, R; Saade, G; Waller, J, 2023)
"Evidence on the risk of preterm preeclampsia was taken from the Screening programme for pre-eclampsia study, which was a first-trimester screening study for the prediction of preeclampsia."	5.72	When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. ( Nicolaides, KH; Tan, MY; Wright, A; Wright, D, 2022)
"Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality."	5.72	Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022)
"To evaluate the effectiveness of a preeclampsia (PE) screening program using the National Institute for Health and Care Excellence (NICE) guideline in pregnant Thai women."	5.72	Low-dose aspirin for prevention of preeclampsia: Implementation of the NICE guideline in Thailand. ( Charernjiratragul, K; Geater, A; Khwankaew, N; Suksai, M; Suntharasaj, T; Suwanrath, C, 2022)
"Reportedly, aspirin prevents preeclampsia, specifically early-onset preeclampsia, although findings in decidual arteries in women treated with aspirin therapy remain unclear."	5.72	Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia. ( Gi, T; Katsuragi, S; Kodama, Y; Maekawa, K; Sameshima, H; Sato, Y; Tomimori-Gi, K; Yamada, N; Yamashita, A, 2022)
"The APPEC study is a large-population randomized controlled trial in China evaluating the role of low-dose aspirin prophylactic treatment for pre-eclampsia."	5.69	Low-dose aspirin in the prevention of pre-eclampsia in China: postpartum hemorrhage in subgroups of women according to their characteristics and potential bleeding risk. ( Chen, J; Huai, J; Li, B; Lin, L; Yang, H; Zhu, Y, 2023)
"The mechanism by which aspirin prevents pre-eclampsia is poorly understood, and its effects on biomarkers throughout pregnancy are unknown."	5.69	ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine artery pulsatility index trajectories in pregnancy. ( Nicolaides, KH; O'Gorman, N; Poon, LC; Rolnik, DL; Syngelaki, A; Wright, D, 2023)
"These findings suggest that individuals with twin pregnancies, a history of preeclampsia, or hypertension may not benefit from aspirin to the same extent as those with other complications such as obesity or diabetes."	5.69	Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. ( Corsi, DJ; Dagvadorj, A; Dingwall-Harvey, ALJ; El-Chaár, D; Gaudet, LM; Guo, Y; McLean, C; Muldoon, KA; Rennicks White, R; Rybak, N; Walker, MC; Wen, SW, 2023)
"The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin."	5.69	The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023)
" Low-dose aspirin is used to prevent pre-eclampsia, which has a similar mechanism; hence, the present study aimed to investigate the effect of low-dose aspirin on the prevention of PTD in women with a history of spontaneous PTD."	5.69	Evaluation of the Effect of Low-dose Aspirin on the Prevention of Preterm Delivery in Women with a History of Spontaneous Preterm Delivery. ( Azadi, P; Bakhtiyari, M; Dehghani, Z; Khavandegar, A; Mirzamoradi, M; Mohammadi, M, 2023)
"· High-risk patients who lack a history preeclampsia were less likely to be advised of aspirin use."	5.62	Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. ( Berghella, V; Boelig, RC; Roman, A; Wanees, M; Zhan, T, 2021)
"Our laboratory demonstrated that preeclampsia is associated with high soluble fms-like tyrosine kinase 1 (sFlt-1) and low heme oxygenase-1 (HO1/Hmox1) expression."	5.62	MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment. ( Agrawal, S; Ahmad, S; Ahmed, A; Alzahrani, FA; Dias, IH; Rezai, H; Sanchez-Aranguren, L; Sparatore, A; Wang, K, 2021)
"Preeclampsia is a severe gestational hypertensive disorder that occurs after 20 weeks' of gestation."	5.62	Aspirin facilitates trophoblast invasion and epithelial-mesenchymal transition by regulating the miR-200-ZEB1 axis in preeclampsia. ( Kuo, PL; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2021)
"The use of aspirin for preventing preeclampsia has been practiced recently by fetomaternal specialists in Indonesia."	5.56	Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia. ( Karunia, RI; Prasetyadi, FOH; Purnamayanti, A, 2020)
"In women who developed severe preeclampsia and delivered preterm, there were significant elevations in non-aspirin-sensitive lipids with biologic actions that could cause preeclampsia."	5.56	Placental Production of Eicosanoids and Sphingolipids in Women Who Developed Preeclampsia on Low-Dose Aspirin. ( Al Dulaimi, M; Alam, SMK; Chalfant, CE; Lee, SM; Reep, DT; Springel, EH; Stephenson, DJ; Strauss, JF; Walsh, SW; Washington, SL, 2020)
"Early-onset preeclampsia was found in 3 pregnant women (0."	5.56	Screening for Preeclampsia in the First Trimester and Aspirin Prophylaxis: Our First Year. ( Caeiro, F; Francisco, C; Gomes, H; Lourenço, I; Ribeiro, J; Rocha, P, 2020)
"The benefit of aspirin in preventing preeclampsia is increasingly recognized; however, its mechanism of action remains unclear."	5.56	The 15-Epilipoxin-A4 Pathway with Prophylactic Aspirin in Preventing Preeclampsia: A Longitudinal Cohort Study. ( Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Motum, P; Shanmugalingam, R; Wang, X, 2020)
"Daily aspirin, started in the first trimester of pregnancy, is commonly used for the prevention of preeclampsia and fetal growth restriction in multiple gestation."	5.51	Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial. ( Boutin, A; Bujold, E; Camiré, B; Carpentier, C; Guerby, P; Tapp, S, 2022)
"The aspirin group was associated with earlier delivery at 38."	5.51	Effect of early use of low-dose aspirin therapy on late-onset preeclampsia. ( Gillin, AG; Hyett, J; Lan, PG; Pelosi, M; Sandager, P; Tooher, J, 2019)
"Aspirin plays an important role in the prevention and therapy of pre-eclampsia."	5.51	Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. ( Ma, Y; Shi, X; Song, L; Yang, S; Zhao, N, 2019)
"Our novel findings suggest that the preeclampsia prevention effect of aspirin may be exerted through these two mechanisms."	5.51	Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. ( Chen, TY; Kuo, PL; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2019)
"Preeclampsia is a hypertensive disorder specific to pregnancy that remains a significant cause of maternal and neonatal morbidity and mortality."	5.48	Low-Dose Aspirin for the Prevention of Preeclampsia. ( Fantasia, HC, 2018)
"Preeclampsia is a severe pregnancy-related disorder, and patients usually present with high circulating inflammatory factor levels and excessive activation of the nuclear factor-κB (NF-κB) pathway."	5.48	The intervention effect of aspirin on a lipopolysaccharide-induced preeclampsia-like mouse model by inhibiting the nuclear factor-κB pathway. ( Li, G; Lin, L; Ma, L; Wang, YL; Yang, H, 2018)
"Aspirin treatment significantly decreased the levels of pro-inflammatory cytokines in serum and placenta tissues of preeclampsia rats."	5.48	Ameliorative effects of aspirin against lipopolysaccharide-induced preeclampsia-like symptoms in rats by inhibiting the pro-inflammatory pathway. ( Liu, F; Lu, X; Sun, J; Tang, D; Zhang, H, 2018)
"Presumed rates of preeclampsia were 3."	5.48	Preeclampsia Prevention Using Routine Versus Screening Test-Indicated Aspirin in Low-Risk Women. ( Breathnach, F; Cotter, A; Daly, S; Dicker, P; Higgins, J; Hunter, A; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Morrison, JJ; Mulcahy, C; Normand, C; O'Mahony, JF; Tully, E; Tyrrell, E, 2018)
"The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations."	5.46	Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017)
"The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies."	5.46	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. ( Carbone, IF; de Alvarado, M; Delgado, JL; Dutemeyer, V; Kapeti, E; Nicolaides, KH; Papantoniou, N; Pazos, A; Plasencia, W; Poon, LC; Rehal, A; Rolnik, DL; Syngelaki, A; Vojtassakova, D; Wright, D, 2017)
"Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity."	5.46	Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women? ( Costantine, MM; Marrs, CC, 2017)
"The estimated rate of preeclampsia would be 4."	5.42	A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States. ( Hauspurg, AK; Rouse, DJ; Werner, EF, 2015)
"We noted a 2."	5.42	Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Winn, VD, 2015)
"Evidence has shown significant benefits of aspirin for preventing pre-eclampsia."	5.41	Prevention of pre-eclampsia with aspirin: A systematic review of guidelines and evaluation of the quality of recommendation evidence. ( Ali, R; McDonald, SD; Morfaw, F; Ninan, K, 2023)
"This systematic review and meta-analysis investigated whether the use of low-dose aspirin during pregnancy by women with chronic hypertension reduces the odds of superimposed preeclampsia and poor perinatal outcomes."	5.41	Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. ( Giorgione, V; Richards, EMF; Stevens, O; Thilaganathan, B, 2023)
"Low-molecular-weight heparin, vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk of preeclampsia/pregnancy-induced hypertension."	5.41	Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. ( Chen, JY; Duan, CY; He, PC; Li, JQ; Liu, YH; Liu, YX; Lye, S; Tan, N; Wang, ZJ; Wei, YX; Xie, NJ; Xu, XJ; Zhang, YS, 2023)
" The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage."	5.41	Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023)
"To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs."	5.41	Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023)
"Recent studies have shown a benefit to more aggressive treatment of mild chronic hypertension to a blood pressure goal of <140/90 with oral labetalol and nifedipine remaining first-line agents."	5.41	Cardiac medications in obstetric patients. ( Albert-Stone, E; Davis, MB; Spehar, SM, 2023)
"This study aimed to compare 2 aspirin dosage regimens for the prevention of preterm preeclampsia (PE): 75 to 81 mg vs 150 to 162 mg taken daily starting in the first trimester of pregnancy."	5.41	Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. ( Bujold, E; Foisy, MA; Ghesquiere, L; Guerby, P; Kumar, N; Marchant, I; Roberge, S; Zare, M, 2023)
" The aim of this narrative review is to investigate the role of blood pressure (BP) monitoring, physical activity, and prophylactic aspirin to reduce the prevalence of preeclampsia and to improve pregnancy outcome in women with preexisting diabetes."	5.41	Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin. ( Damm, P; Do, NC; Mathiesen, ER; Nørgaard, SK; Ringholm, L; Vestgaard, M, 2023)
"Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth."	5.41	Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023)
"To examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre-eclampsia (PE)-specific biomarkers and estimated-risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis."	5.41	ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. ( Martinez-Portilla, RJ; Poon, LC; Rolnik, DL; Shen, L, 2021)
"The residual risk of preeclampsia in high-risk women on aspirin prophylaxis exceeds that of low-risk populations, and this study aimed to identify first-trimester maternal characteristics associated with aspirin prophylaxis failure."	5.40	First-trimester risk factors for preeclampsia development in women initiating aspirin by 16 weeks of gestation. ( Atlas, RO; Baschat, AA; Blitzer, MG; Block-Abraham, DM; Doyle, LE; Jenkins, CB; Kopelman, JN; Turan, OM, 2014)
" Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation."	5.34	Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. ( Achieng, E; Bose, CL; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Miodovnik, M; Moore, J; Mwapule, A; Mwenechanya, M; Nolen, TL; Nyongesa, P; Okitawutshu, J; Patel, A; Saleem, S; Silver, R; Somannavar, M; Tshefu, A; Zehra, F, 2020)
"To evaluate the preventive effects of low-dose aspirin on the incidence of preeclampsia and pregnancy outcomes of women at high-risk for preeclampsia."	5.34	Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes: A randomized controlled trial from Shanghai, China. ( Gu, W; Hou, YY; Huang, HF; Lin, J; Lin, N; Shang, J; Song, MF; Zeng, WJ, 2020)
" The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy."	5.34	The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020)
"We observed no significant difference in UtA-PI between the two doses of aspirin, but we observed low rates of fetal growth restriction and preterm and early-onset preeclampsia (all less than 5%)."	5.34	A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on Midtrimester Uterine Artery Pulsatility Index in Women with a History of Preeclampsia. ( Bujold, E; Côté, S; Ferreira, E; Girard, M; Guerby, P; Leclair, G; Roberge, S; Tapp, S, 2020)
"This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines."	5.34	Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020)
"This article evaluates the effect of low-dose aspirin on uterine artery (UtA) Doppler, placental volume, and vascularization flow indices in low-risk pregnancy."	5.30	The Impact of Aspirin on Ultrasound Markers of Uteroplacental Flow in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Breathnach, F; Cody, F; Cotter, A; Daly, S; Dicker, P; Dornan, S; Higgins, J; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Morrison, JJ; Mulcahy, C; Tully, E, 2019)
"To assess the effect of aspirin use in low-risk pregnancy on: (1) pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) fetal growth parameters; and (4) placental histopathology."	5.30	Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Clarke, P; Culliton, M; Downey, P; Fitzgerald, D; Maguire, OC; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Mooney, EE; Mulcahy, C; Tully, E, 2019)
"There is a reduction in the total drug metabolite concentration of aspirin in pregnancy, and therefore a dose adjustment is potentially required in pregnant women."	5.30	A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. ( Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)
"Prophylactic LMW heparin therapy when beginning from before 14 weeks of gestation with aspirin during pregnancy is not associated with an improved angiogenic profile."	5.27	Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis. ( Cochery-Nouvellon, E; Gris, JC; Haddad, B; Karumanchi, SA; Lecarpentier, E; Mercier, E; Thadhani, R; Touboul, C, 2018)
"Our objective was to determine whether low-dose aspirin reduces the rate of spontaneous preterm birth in nulliparous women without medical comorbidities."	5.27	Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. ( Andrikopoulou, M; Gyamfi-Bannerman, C; Handal-Orefice, R; Purisch, SE, 2018)
"Evaluate the feasibility and acceptability of routine aspirin in low-risk women, compared with screening-test indicated aspirin for the prevention of pre-eclampsia and fetal growth restriction."	5.27	( Alfirevic, Z; Breathnach, F; Cody, F; Cotter, A; Culliton, M; Daly, S; Dicker, P; Downey, P; Higgins, J; Hunter, A; Malone, FD; McAuliffe, FM; McCormack, D; McParland, P; Mone, F; Morrison, JJ; Mulcahy, C; Stanton, A; Tully, EC, 2018)
" Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin."	5.24	A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017)
" It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia."	5.24	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Gizurarson, S; Janga, D; Jani, JC; Maclagan, K; Meiri, H; Molina, FS; Nicolaides, KH; O'Gorman, N; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tenenbaum-Gavish, K; Wright, D, 2017)
"To examine the performance of screening for preterm and term pre-eclampsia (PE) in the study population participating in the ASPRE (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) trial."	5.24	ASPRE trial: performance of screening for preterm pre-eclampsia. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Janga, D; Jani, JC; Molina, FS; Nicolaides, KH; O'Gorman, N; Papaioannou, G; Persico, N; Plasencia, W; Poon, LCY; Rolnik, DL; Singh, M; Syngelaki, A; Tenenbaum-Gavish, K; Wright, D, 2017)
"In women with defective trophoblastic invasion, as reflected by abnormal UtA Doppler, low-dose aspirin started in the first trimester does not have a significant effect on UtA impedance as pregnancy progresses; however, the study was underpowered to detect potential small effects ."	5.24	Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. ( Diaz, D; Figueras, F; González de Agüero, R; Gratacos, E; Meler, E; Oros, D; Ramirez, JC; Ricart, M; Scazzocchio, E, 2017)
"There is a lack of evidence for pre-eclampsia prophylaxis with aspirin in women with pre-existing diabetes mellitus (DM)."	5.22	Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review. ( Alahakoon, TI; Cheung, NW; Haider, R; Jesudason, S; Lee, VW; Nolan, CJ; Padmanabhan, S; Peek, M; Simmons, D; Zen, M, 2022)
"To evaluate the association between the use of low-dose aspirin for preeclampsia prophylaxis and risks of gestational diabetes (primary outcome), neonatal hypoglycemia, macrosomia, large for gestational age, birth trauma, and shoulder dystocia (secondary outcomes)."	5.22	Association Between Low-Dose Aspirin and Development of Gestational Diabetes: A Systematic Review and Meta-Analysis. ( Burwick, R; Chauhan, SP; Gupta, M; Mendez-Figueroa, H; Murphy, L; Saldanha, IJ; Sawyer, K; Wagner, SM, 2022)
" The following were consistently recommended: (1) automated blood pressure measurement with devices validated for pregnancy and preeclampsia, reflecting increasing recognition of the prevalence of white-coat hypertension and the potential usefulness of home blood pressure monitoring; (2) use of dipstick proteinuria testing for screening followed by quantitative testing by urinary protein-to-creatinine ratio or 24-hour urine collection; (3) key definitions and most aspects of classification, including a broad definition of preeclampsia (which includes proteinuria and maternal end-organ dysfunction, including headache and visual symptoms and laboratory abnormalities of platelets, creatinine, or liver enzymes) and a recognition that it can worsen after delivery; (4) preeclampsia prevention with aspirin; (5) treatment of severe hypertension, most commonly with intravenous labetalol, oral nifedipine, or intravenous hydralazine; (6) treatment for nonsevere hypertension when undertaken, with oral labetalol (in particular), methyldopa, or nifedipine, with recommendations against the use of renin-angiotensin-aldosterone inhibitors; (7) magnesium sulfate for eclampsia treatment and prevention among women with "severe" preeclampsia; (8) antenatal corticosteroids for preterm birth but not hemolysis, elevated liver enzymes, and low platelet count syndrome; (9) delivery at term for preeclampsia; (10) a focus on usual labor and delivery care but avoidance of ergometrine; and (11) an appreciation that long-term health complications are increased in incidence, mandating lifestyle change and risk factor modification."	5.22	Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. ( Gillon, TE; Magee, LA; Pels, A; Scott, G; von Dadelszen, P, 2022)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."	5.22	Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The objective of this study is to determine whether low-dose aspirin (LDA) reduced the rate of preterm birth (PTB) in a cohort of women at high risk for preeclampsia."	5.22	The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. ( Allshouse, AA; Heyborne, KD; Jessel, RH, 2016)
"The objective of the study is to evaluate low-dose aspirin (LDA) for pre-eclampsia prevention in twin gestations with elevated maternal serum human chorionic gonadotropin (hCG)."	5.22	Low-dose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin. ( Allshouse, AA; Euser, AG; Heyborne, KD; Metz, TD, 2016)
"We propose a three armed multi-center open-labeled randomized control trial of; (i) routine LDA, (ii) no aspirin, and (iii) LDA on the basis of a positive first trimester pre-eclampsia screening test."	5.22	An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. ( Breathnach, F; Culliton, M; Dicker, P; Downey, P; Malone, FD; McAuliffe, FM; McCormack, D; McParland, P; Mone, F; Mulcahy, C; Stanton, A; Tully, E, 2016)
"The aim of this study is to analyze the effect of 100 mg/d regular oral intake of aspirin during pregnancy on high-risk pregnancy-induced hypertension syndrome patients."	5.22	Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016)
"Late timing of intervention and maternal obesity are potential explanations for the modest effect of aspirin for preeclampsia prevention."	5.20	Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? ( Abramovici, AR; Biggio, JR; Cantu, JA; Edwards, RK; Jauk, VR; Owen, J; Tita, AT, 2015)
"Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort."	5.20	Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015)
"To estimate the effect of early administration of aspirin on the prevention of pre-eclampsia in high-risk women."	5.20	Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. ( Goetzinger, KR; Odibo, AO; Odibo, L; Tuuli, MG, 2015)
"To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2."	5.19	Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014)
"Adding low-molecular-weight heparin (LMWH) to aspirin at < 12 weeks gestation reduces the recurrence of HD in women with previous early-onset HD (pre-eclampsia, hemolysis, elevated liver enzymes and low platelets [HELLP] syndrome and eclampsia) and/or SGA, in the context of inheritable thrombophilia without antiphospholipid antibodies."	5.16	Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. ( Bezemer, PD; de Vries, JI; Hague, WM; Joosten, JH; van Pampus, MG, 2012)
"Low-dose aspirin therapy could improve remodelling of maternal spiral arteries during early placentation and prevent subsequent pregnancy-related hypertensive disorders."	5.14	Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010)
"Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure."	5.12	Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021)
" We included randomized controlled trials reporting on health-related outcomes in children (aged > 28 days) exposed to aspirin versus placebo or no treatment during pregnancy."	5.12	Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. ( de Boer, MA; Finken, MJJ; Ket, JCF; Landman, AJEMC; Leemhuis, AG; Oudijk, MA; Painter, RC; van 't Hooft, J; van Limburg Stirum, EVJ, 2021)
"The use of low dose aspirin (LDA) has become routine in prenatal care for a variety of diagnoses, most importantly in women with a history of preeclampsia and associated poor pregnancy outcomes."	5.12	Low-dose aspirin in pregnancy: who? when? how much? and why? ( Dom, AM; Mather, AR; Thorburg, LL, 2021)
" Aspirin prophylaxis substantially lowered the risk of pre-eclampsia, preterm birth, perinatal mortality, and intrauterine growth retardation without elevated bleeding risks."	5.12	Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis. ( Choi, YJ; Shin, S, 2021)
"The results did not demonstrate a significant difference amongst low risk nulliparous women in the risks of pre-eclampsia or gestational hypertensive disorders with aspirin administration."	5.12	Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. ( Devani, P; Hodgetts Morton, V; Man, R; Morris, RK, 2021)
"To verify whether prophylaxis with low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA) could positively affect pregnancy outcome in women with a history of severe preeclampsia."	5.12	Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. ( Alessandro, C; Gabriella, F; Giancarlo, P; Giorgia, S; Maria Clara, D; Sergio, F, 2006)
"To determine if aspirin (ASA) therapy reduces the incidence of pre-eclampsia in women at high risk of this condition."	5.11	A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia. ( Acaia, B; Chiaffarino, F; Del Giudice, A; Facchinetti, F; Marozio, L; Ossola, W; Paladini, D; Parazzini, F, 2004)
"To reduce the incidence of pre-eclampsia in nulliparous women, in accordance with the suggestion of a recent meta-analysis that low dose aspirin might decrease this incidence by more than half if used early enough in and at a sufficient dose during pregnancy (more than 75 mg)."	5.10	Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). ( Biausque, S; Breart, G; Churlet, A; Goeusse, P; Lequien, P; Marquis, P; Parmentier, D; Puech, F; Subtil, D; Uzan, S, 2003)
"To assess the effectiveness of a pre-eclampsia prevention strategy based on routine uterine artery Doppler flow velocity waveform examination during the second trimester of pregnancy, followed by a prescription for 100 mg aspirin in the case of abnormal Doppler findings."	5.10	Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2). ( Breart, G; Delcourt, YM; Goeusse, P; Houfflin-Debarge, V; Lequien, P; Malek, YM; Puech, F; Quandalle, F; Subtil, D; Uzan, S, 2003)
"In pregnancies with impaired placentation, as demonstrated by increased impedance to flow in the uterine arteries, the daily administration of 150 mg aspirin after 23 weeks of gestation does not prevent the subsequent development of pre-eclampsia."	5.10	Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. ( Nicolaides, KH; Palma Dias, R; Papageorghiou, AT; Parra, M; Yu, CK, 2003)
"This study extends previous results on the effects of low-dose aspirin on blood pressure in pregnant women at differing risk of developing hypertension in pregnancy and who received aspirin at different times according to their rest-activity cycle."	5.09	Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. ( Alonso, I; Ayala, DE; Codesido, J; Fernández, JR; Hermida, RC; Iglesías, M; Mojón, A; Silva, I; Ucieda, R, 1999)
"This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention."	5.09	Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000)
"To investigate the effect of low-dose, slow-release aspirin in reducing the incidence and/or severity of pregnancy complications in women identified as high risk of developing problems associated with uteroplacental insufficiency, namely pre-eclampsia or delivering a small-for-gestational age (SGA) baby."	5.09	A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. ( Aquilina, J; Campbell, S; England, P; Harrington, K; Kurdi, W, 2000)
"Daily administration of low-dose aspirin during the second and third trimesters of pregnancy does not alter uteroplacental or fetoplacental hemodynamics and does not cause moderate or severe constriction of the ductus arteriosus."	5.09	Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. ( Erdmann, M; Grab, D; Kreienberg, R; Lang, D; Muche, R; Oberhoffer, R; Paulus, WE; Terinde, R, 2000)
"To assess whether systematic screening with an uterine artery Doppler in low risk pregnant women followed by the prescription of low dose aspirin in cases with abnormal results reduced the incidence of intrauterine growth restriction and pre-eclampsia."	5.09	Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. ( Aboulker, D; Bréart, G; Bucourt, M; Goffinet, F; Papiernik, E; Paris-Llado, J; Uzan, M, 2001)
"Aspirin therapy increased birth weight in all women, especially in women with high human chorionic gonadotropin levels, partly by increasing gestational age at delivery."	5.08	The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. ( DuBard, MB; Goldenberg, RL; Hauth, JC; Lea, C; Wenstrom, KD, 1995)
" The angiotensin II-sensitive women were randomized to 60 mg of aspirin or placebo as a subset of a large multicenter, randomized, controlled trial of low-dose aspirin therapy in pregnancy."	5.08	The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. ( Buckley, D; de Swiet, M; Kissane, J; Kyle, PM; Redman, CW, 1995)
" Whether patients were assigned to aspirin or placebo, birth weight was significantly greater in women who had a twofold or greater reduction in maternal serum thromboxane B2 levels."	5.08	Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. ( Copper, RL; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995)
"Our purpose was to determine the frequency and safety of the use of epidural anesthesia and the correlation between bleeding time and maternal-neonatal bleeding complications in a group of pregnant women who participated in a multicenter trial of low-dose aspirin in pregnancy."	5.08	Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. ( Caritis, SN; McNellis, D; Shaw, K; Sibai, BM; Thom, E, 1995)
"To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation."	5.08	Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995)
"To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia."	5.08	ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996)
"To assess the effect of low dose aspirin on severe pre-eclampsia when given to women identified as high risk by abnormal uterine artery Doppler ultrasound."	5.08	Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. ( Bower, SJ; Campbell, S; Harrington, KF; McGirr, C; Schuchter, K, 1996)
"To analyze determinants of the risk of pregnancy-induced hypertension (PIH) with or without proteinuria, we compared characteristics of women enrolled in the Italian Study of Aspirin in Pregnancy who developed PIH and those who did not."	5.08	Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. ( Benedetto, C; Bortolus, R; Chatenoud, L; Marozio, L; Parazzini, F; Restelli, S; Ricci, E, 1996)
"There is evidence that aspirin in low doses favourably influences the course and outcome of pregnancy in women at risk of developing pregnancy-induced hypertension."	5.08	Low dose aspirin in prevention of pregnancy-induced hypertension in primigravidae at the Muhimbili Medical Center, Dar es Salaam. ( Mgaya, HN; Ramaiya, C, 1995)
"The use of low-dose aspirin for the prevention and treatment of pre-eclampsia and intrauterine growth restriction has been studied extensively during the last 10 years."	5.08	Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. ( Bar, J; Fisch, B; Hod, M; Kaplan, B; Meizner, I; Pardo, J; Rabinerson, D, 1997)
"We found an association between the addition of ketanserin to aspirin and a decrease in the number of cases of pre-eclampsia and severe hypertension, as well as improved pregnancy outcome among patients with mild to moderate midtrimester hypertension."	5.08	Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. ( Odendaal, HJ; Steyn, DW, 1997)
"To determine whether low-dose aspirin reduces the incidence of pre-eclampsia, reduces perinatal mortality and improves birth weights in pregnant women considered at high risk of developing pre-eclampsia."	5.08	A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. ( Byaruhanga, RN; Chipato, T; Rusakaniko, S, 1998)
"The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings."	5.08	Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998)
"To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation."	5.08	A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998)
"We studied 2503 women with either diabetes mellitus, chronic hypertension, multifetal gestation, or pre-eclampsia in a previous pregnancy who participated in a multicenter study comparing aspirin and placebo in preventing pre-eclampsia."	5.08	Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998)
"Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders."	5.07	Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993)
"Concern has been expressed about possible neonatal side effects after the use of maternal anti-platelet agents in pregnancy, particularly low dose aspirin treatment."	5.07	Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin. ( Broughton Pipkin, F; Fox, SC; Heptinstall, S; Louden, KA; Mitchell, JR; O'Callaghan, C; Symonds, EM; Tuohy, P, 1994)
"To study the effect of daily treatment with 50 mg of aspirin (ASA) on the hypertensive pregnancy complications and on the production prostacyclin (PGI2) and thromboxane A2 (TxA2) in high risk pregnant women and their infants."	5.07	Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. ( Hartikainen-Sorri, AL; Hiilesmaa, V; Lumme, R; Viinikka, L; Ylikorkala, O, 1993)
"Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia."	5.07	Low-dose aspirin therapy to prevent preeclampsia. ( Copper, RL; Cutter, GR; DuBard, MB; Goldenberg, RL; Hauth, JC; Parker, CR; Philips, JB, 1993)
"In a prospective, randomized, double-blind study for the prevention of pregnancy-induced hypertension and preeclampsia, 41 primigravidae with positive roll-over test (28th-32nd week of pregnancy) received 80 mg aspirin/day or placebo until the end of the 37th week."	5.07	Low-dose aspirin in primigravidae with positive roll-over test. ( Alge, A; Dapunt, O; Daxenbichler, G; Hansen, H; Pastner, E; Schröcksnadel, H; Schwegel, P; Sitte, B; Steckel-Berger, G, 1992)
"A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia."	5.07	Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991)
"The hypothesis that an enhanced vasopressor response to angiotensin II in pregnancy may be corrected by suppressing production of platelet thromboxane A2 with low-dose aspirin was tested in a randomized, placebo-controlled, double-blind trial."	5.07	Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women. ( Dekker, GA; Makovitz, JW; Rotmans, N; Wallenburg, HC, 1991)
"The effect of low doses of aspirin on women with mild pregnancy-induced hypertension was investigated by means of a prospective, randomized, double-blind trial."	5.06	Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension. ( Barkai, G; Ben-Baruch, G; Mashiach, S; Schiff, E, 1990)
"We carried out a prospective, randomized, double-blind, placebo-controlled study to investigate the capacity of aspirin to prevent pregnancy-induced hypertension and to alter prostaglandin metabolism."	5.06	The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. ( Barkai, G; Ben-Baruch, G; Blankstein, J; Goldenberg, M; Peleg, E; Rosenthal, T; Ruppin, E; Schiff, E; Tamarkin, M; Yahal, I, 1989)
"The possibility of preventing pregnancy-induced hypertension (PIH) and pre-eclampsia in primigravidae by suppressing production of thromboxane A2 with low-dose aspirin was investigated in a randomised, placebo-controlled, double-blind trial."	5.06	Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. ( Dekker, GA; Makovitz, JW; Rotmans, P; Wallenburg, HC, 1986)
"Since the 1970s, we have known that aspirin can reduce the risk of pre-eclampsia."	5.05	Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition? ( Danser, AHJ; Mirabito Colafella, KM; Neuman, RI; Versmissen, J; Visser, W, 2020)
"To perform a meta-analysis and meta-regression of randomized controlled trials (RCTs) to evaluate the impact of low-dose aspirin (LDA) on perinatal outcome, independent of its effect on pre-eclampsia (PE), preterm birth and low birth weight."	5.05	Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. ( Hartel, G; Kumar, S; Robertson, NT; Turner, JM, 2020)
"We performed a systematic review and meta-analysis to evaluate the effect of low-dose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy."	5.05	Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? ( Chaemsaithong, P; Cuenca-Gomez, D; Gil, MM; Plana, MN; Poon, LC, 2020)
"For the past decades, growing attention has been given to aspirin use during pregnancy."	5.05	Aspirin for prevention of preeclampsia and fetal growth restriction. ( Guerby, P; Hamdi, SM; Loussert, L; Parant, O; Vayssiere, C; Vidal, F, 2020)
"Aspirin and heparin are widely used as preventive strategy to reduce the high risk of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL)."	5.05	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. ( Goddijn, M; Hamulyák, EN; Marijnen, MC; Middeldorp, S; Scheres, LJ, 2020)
"Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration."	5.05	Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020)
" Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes."	5.05	The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020)
"102 patients at high risk of pre-eclampsia and/or fetal growth retardation were randomly allocated to treatment with 300 mg dipyridamole and 150 mg aspirin daily from 3 months' gestation onwards (group A) or to the control group (group B, no treatment)."	5.05	Prevention of pre-eclampsia by early antiplatelet therapy. ( Beaufils, M; Colau, JC; Donsimoni, R; Uzan, S, 1985)
"Administering low-dose aspirin to pregnant women led to small-to-moderate benefits, including reductions in pre-eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small-for-gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated)."	5.01	Antiplatelet agents for preventing pre-eclampsia and its complications. ( Askie, LM; Duley, L; Hunter, KE; Meher, S; Seidler, AL, 2019)
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."	5.01	[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"We performed a systematic review and metaanalysis that evaluated the prophylactic effect of aspirin during pregnancy."	4.98	Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018)
"We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug."	4.98	Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018)
"To assess the accuracy of the National Institute of Health and Care Excellence (NICE) and United States Preventive Services Task Force (USPSTF) guidelines for predicting pre-eclampsia in pregnancy to guide aspirin prophylaxis."	4.98	Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis. ( Al-Rubaie, ZTA; Askie, LM; Hudson, HM; Jenkins, G; Lord, SJ; Ray, JG, 2018)
"The use of aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS have a successful pregnancy outcome."	4.95	Current insights in obstetric antiphospholipid syndrome. ( Radin, M; Schreiber, K; Sciascia, S, 2017)
"Low-dose aspirin (LDA) is advocated for women at high-risk of pre-eclampsia, providing a modest, 10%, reduction in risk."	4.95	How important is aspirin adherence when evaluating effectiveness of low-dose aspirin? ( Alfirevic, A; Alfirevic, Z; Navaratnam, K; Pirmohamed, M, 2017)
"We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction."	4.95	The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. ( Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017)
"To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone."	4.93	Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016)
"To estimate the impact of adding low-molecular-weight heparin (LMWH) or unfractionated heparin to low-dose aspirin started ≤ 16 weeks' gestation on the prevalence of pre-eclampsia (PE) and the delivery of a small-for-gestational-age (SGA) neonate."	4.93	Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. ( Bujold, E; Bureau, M; Côté, S; Demers, S; Nicolaides, KH; Roberge, S, 2016)
" Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia that can be prevented using soluble low-dose aspirin treatment started before 16 weeks of gestation."	4.93	Development of prenatal screening--A historical overview. ( Cuckle, H; Maymon, R, 2016)
" Individual patient data meta-analysis indicates that low-dose aspirin causes a 10% risk reduction in pre-eclampsia for women at high individual risk."	4.93	Low dose aspirin and pregnancy: how important is aspirin resistance? ( Alfirevic, A; Alfirevic, Z; Navaratnam, K, 2016)
"Risk prediction models may be valuable to identify women at risk of pre-eclampsia to guide aspirin prophylaxis in early pregnancy."	4.93	The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review. ( Al-Rubaie, Z; Askie, LM; Hudson, HM; Lord, SJ; Ray, JG, 2016)
"This review examines the recent literature on the use of low-dose aspirin (LDA) for primary and secondary prevention of cardiovascular disease in women, use of LDA for pre-eclampsia prevention in pregnancy, and the underutilization of aspirin therapy in women as compared to men."	4.93	Aspirin Use in Women: Current Perspectives and Future Directions. ( Sarma, A; Scott, NS, 2016)
"Low-dose aspirin (LDA) is thought to prevent preeclampsia in high-risk pregnancy, but it is not universally used out of concern for its efficacy and safety."	4.91	Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. ( Deng, CY; Huang, GQ; Li, JK; Wang, XD; Xu, TT; Zhou, F, 2015)
"In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight."	4.91	[Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015)
" Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events."	4.90	Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014)
"Databases were searched for keywords related to aspirin and pregnancy."	4.89	Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. ( Bujold, E; Demers, S; Nicolaides, KH; Roberge, S; Villa, P, 2013)
" Several studies verify whether prophylaxis with low molecular weight heparins and low dose aspirin could improve pregnancy outcome in preeclampsia."	4.88	[The possible options for the prevention of preeclampsia]. ( Fodor, A; Fülesdi, B; Gyorffy, A; Major, T; Váradi, M, 2012)
" We sought to review the effect of aspirin, calcium supplementation, antihypertensive agents and magnesium sulphate on risk stillbirths."	4.87	Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths. ( Bhutta, ZA; Imdad, A; Jabeen, M; Yakoob, MY, 2011)
"The aim of this study is to review literature about the efficacy of low dose aspirin (LDA) and vitamins C/E (VCE) to prevent pre-eclampsia in women at high and low risk."	4.87	Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. ( Mullin, PM; Rossi, AC, 2011)
"To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)."	4.86	Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010)
"Investigate cost-effectiveness of first trimester pre-eclampsia screening using the Fetal Medicine Foundation (FMF) algorithm and targeted aspirin prophylaxis in comparison with standard care."	4.84	First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study. ( Ammari, C; Casagrandi, D; Hillman, S; Napolitano, R; Nzelu, D; Palmer, T; Pandya, P; Stott, D, 2024)
"Antiplatelet agents, largely low-dose aspirin, have moderate benefits when used for prevention of pre-eclampsia and its consequences."	4.84	Antiplatelet agents for preventing pre-eclampsia and its complications. ( Duley, L; Henderson-Smart, DJ; King, JF; Meher, S, 2007)
"Antiplatelet agents, in this review largely low dose aspirin, have small-moderate benefits when used for prevention of pre-eclampsia."	4.84	WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia. ( Duley, L; Henderson-Smart, DJ; King, JF; Knight, M, 2007)
"Antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia."	4.81	Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. ( Duley, L; Henderson-Smart, D; King, J; Knight, M, 2001)
"Antiplatelet agents, in this review largely low dose aspirin, have small-moderate benefits when used for prevention of pre-eclampsia."	4.80	Antiplatelet agents for preventing and treating pre-eclampsia. ( Duley, L; Henderson-Smart, DJ; King, JF; Knight, M, 2000)
"To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality."	4.79	Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995)
"The results of four large controlled clinical trials, encompassing over 13,000 pregnant women, indicate that low-dose aspirin is of benefit in the prevention of pre-eclampsia in women at high risk."	4.79	Low-dose aspirin therapy in obstetrics. ( Wallenburg, HC, 1995)
"The disparate results reported in the literature on the effects of low dose aspirin in preventing pre-eclampsia might be caused by non-compliance in the more recent large trials in low-risk patients."	4.79	The pharmacological prevention of pre-eclampsia. ( Dekker, GA, 1995)
"Our results demonstrated that the combination of quercetin and aspirin exerted significantly stronger effects than aspirin alone on decreasing systolic blood pressure and proteinuria, reducing pro-inflammatory cytokine production, and inhibiting M1-type decidual macrophages polarization in an LPS-induced rat model of preeclampsia."	4.31	Natural Flavonoid Quercetin Enhances the Anti-inflammatory Effects of Aspirin in a Preeclampsia-like Rat Model Induced by Lipopolysaccharide. ( Chen, D; Ding, J; Liu, A; Yang, S, 2023)
"Treatment with curcumin and aspirin combination significantly reduced the systolic blood pressure and proteinuria in the PE rats."	4.31	Combining curcumin and aspirin ameliorates preeclampsia-like symptoms by inhibiting the placental TLR4/NF-κB signaling pathway in rats. ( Feng, Y; Hou, X; Ju, Y; Wang, Y; Yang, M; Yang, Y; Zhang, X; Zhu, X, 2023)
"The purpose of this study was to assess obstetrician-gynecologist utilization of low-dose aspirin for women at increased risk for hypertensive disorders of pregnancy using guidelines developed by the American College of Obstetricians and Gynecologists and supported by the United States Preventive Services Task Force."	4.31	Relationship between risk factor profile and prescription of low-dose aspirin for preeclampsia prevention. ( Holmgren, C; Phelps, AJD, 2023)
"Many clinical trials have reported that low-dose aspirin decreases the risk of pre-eclampsia in women with prior pre-eclampsia."	4.31	Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study. ( Blacher, J; Deneux-Tharaux, C; Gabet, A; Grave, C; Kretz, S; Lailler, G; Olie, V; Plu-Bureau, G; Regnault, N; Tsatsaris, V, 2023)
"To investigate the effectiveness of low-dose aspirin (LDA) in the prevention of pre-eclampsia (PE) among otherwise low-risk twin gestations."	4.31	Reconsidering the effectiveness of low-dose aspirin in prevention of pre-eclampsia among otherwise low risk twin gestations: A historical cohort study. ( Brantz, Y; Farhi, A; Lerner-Geva, L; Maymon, D; Mazaki-Tovi, S; Meyer, R; Toussia-Cohen, S; Tsur, A; Yinon, Y; Zaslavsky-Paltiel, I, 2023)
"Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia."	4.31	Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. ( Combs, CA; Kumar, NR; Morgan, JL, 2023)
"To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)."	4.31	The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023)
"Adherence to low-dose aspirin is key in preventing pre-eclampsia."	4.31	Let's talk aspirin: A survey of barriers and facilitators faced by midwives when engaging in conversations about aspirin with women at risk of pre-eclampsia. ( Araújo-Soares, V; Farnworth, A; Hiu, S; McParlin, C; Smith, V; Vinogradov, R, 2023)
"Current guidelines recommend low-dose aspirin for preeclampsia prophylaxis in all women with pregestational (type one and type two) diabetes mellitus."	4.12	Associations between aspirin prophylaxis and fetal growth and preeclampsia in women with pregestational diabetes. ( Graham, DF; Shrestha Khatri, N; White, SW, 2022)
"To compare the predictive performance for preterm-pre-eclampsia (PE) in first-trimester screening by serum placental growth factor (PlGF) versus pregnancy associated plasma protein-A (PAPP-A), in combination with maternal risk factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI), after adjustment for the effect of aspirin in women receiving this treatment."	4.12	Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. ( Nicolaides, KH; O'Gorman, N; Syngelaki, A; Tan, MY; Wright, D, 2022)
"To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk."	4.12	Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022)
"To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy."	4.12	Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022)
"Clinical studies suggest that early pregnancy is the critical window for the prevention of preeclampsia by low-dose aspirin (LDA)."	4.12	Low-dose aspirin prevents LPS-induced preeclampsia-like phenotype via AQP-1 and the MAPK/ERK 1/2 pathway. ( Feng, L; Jing, S; Xie, H; Zhang, H; Zhang, J, 2022)
"The use of 100 mg of aspirin a day before the 20th week of pregnancy in high risk pregnant patients decreased the risk of developing PREEC, regardless the age and risk factors."	4.12	[Use of aspirin 100 mg / day to prevent Preeclampsia, in high risk pregnancies, in a cohort from Argentina]. ( Espeche, WG; Minetto, J; Salazar, MR, 2022)
"Aspirin is a common drug for the treatment of pre-eclampsia."	4.12	Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome. ( Chen, D; Ding, J; Song, L; Yang, S; Zhang, J; Zhang, Y, 2022)
"To determine the impact of low-dose aspirin (81 mg) on markers of maternal inflammation and placental function."	4.12	The impact of low-dose aspirin on markers of inflammation and placental function: an ancillary study of the ASPIRIN trial. ( Araganji, R; Goudar, SS; Hoffman, MK; Kavi, A; Somannavar, MS; Vernekar, SS, 2022)
"A retrospective study of 32 women with severe recurrent placenta-mediated complications (preeclampsia with severe features, placental abruption, severe intrauterine growth retardation or intra uterine fetal death) in spite of treatment with low molecular weight heparin and low dose aspirin in previous pregnancy."	4.12	Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study. ( Asher-Landsberg, J; Gamzu, R; Kliger, C; Kupferminc, MJ; Rimon, E; Skornick-Rapaport, A; Yogev, Y, 2022)
"The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia."	4.02	Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021)
" Digital tools such as the MyHealthyPregnancy app might offer an opportunity to improve identification of patients at risk for preeclampsia and communication with these patients about aspirin use."	4.02	Use of a Smartphone App to Explore Potential Underuse of Prophylactic Aspirin for Preeclampsia. ( Bernard, M; Davis, AL; Hayani, L; Krishnamurti, T; Rodriguez, S; Simhan, HN, 2021)
" Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy."	4.02	Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021)
"Aspirin is widely used to prevent pregnancy related vascular disorders such as preeclampsia (PE), intrauterine growth restriction and maternal disorders."	4.02	Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta analysis. ( Dorsamy, V; Khaliq, OP; Mkhize, PZ; Moodley, J; Phoswa, WN, 2021)
"Decision tree analysis was created using R software to evaluate four approaches to aspirin prophylaxis in the United States: no aspirin, United States Preventive Service Task Force (USPSTF) with Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) hypertension guidelines, USPSTF with ACC/AHA hypertension guidelines, as well as universal aspirin prophylaxis."	4.02	The Impact of the New Hypertension Guidelines to Low-Dose Aspirin Prophylaxis Eligibility for the Prevention of Preeclampsia: A Cost-Benefit Analysis. ( Balasooriya, MM; Boscia, AL; Dalkiran, E; Putra, M; Sokol, RJ, 2021)
"53) with a concurrent increase in targeted aspirin use in women classified as high risk for pre-eclampsia (28."	4.02	Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. ( Buck, E; Diaz Gomez, D; Forenc, K; Guy, GP; Khalil, A; Leslie, K; Thilaganathan, B, 2021)
"To evaluate the effects of low-molecular-weight heparin (LMWH) combined with low-dose aspirin (LDA) in pregnant women with a history of pregnancy-related hypertensive disorders."	4.02	Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study. ( Chen, Y; Shen, F; Wang, J; Yang, W; Zhang, Y; Zhou, J, 2021)
"Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)."	4.02	Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021)
"Aspirin is routinely prescribed in high-risk pregnancies to prevent pre-eclampsia; however, there is a paucity of data in women with pre-existing diabetes."	4.02	Aspirin and pre-eclampsia prevention in women with pre-existing diabetes: a retrospective study. ( Athayde, N; Cheung, NW; Inglis, E; Lah, S; Lee, V; Padmanabhan, S, 2021)
"The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD)."	4.02	Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study : This is the study for kidney and pregnancy... ( Chen, Q; Chen, S; He, Y; Wang, M; Yang, H; Zhao, M, 2021)
"Despite being key to reducing the occurrence of pre-eclampsia in high-risk women, adherence to aspirin prophylaxis is low, reflecting multifactorial challenges faced by pregnant women."	4.02	Informational needs related to aspirin prophylactic therapy amongst pregnant women at risk of preeclampsia - A qualitative study. ( Araujo-Soares, V; Robson, SC; Smith, VJ; Vinogradov, R, 2021)
"Plasma from women with pre-eclampsia induced TBARS and nitrotyrosine production on endothelial and U937 cells."	3.96	Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia. ( Alvarez, AM; Cadavid J, AP; Gil-Villa, AM; Rojas-López, M; Velásquez-Berrío, M, 2020)
"The study is aimed at understanding the factors, from the women's perspective, that influenced adherence with prophylactic aspirin in their pregnancy."	3.96	Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis. ( Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Liamputtong, P; Makris, A; Mengesha, Z; Notaras, S; Shanmugalingam, R, 2020)
"To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings."	3.96	Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020)
"To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo."	3.96	Maternal cardiac function in women at high risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study. ( Bisquera, A; Jara, PG; Kametas, NA; Ling, HZ; Nicolaides, KH; Poon, LC, 2020)
"(1) To evaluate the rates of implementation of the 2016 American College of Obstetricians and Gynecologists guideline over time; and (2) to evaluate the effectiveness of aspirin for the prevention of superimposed preeclampsia and other adverse maternal and neonatal outcomes in women with chronic hypertension before and after this guideline."	3.96	Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension. ( Banala, C; Berghella, V; Boelig, RC; Cruz, Y; Moreno, S; Roman, A; Saccone, G; Schoen, CN, 2020)
"A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)."	3.96	Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020)
"We designed a decision analysis to compare preeclampsia-related costs and effects of four strategies for aspirin use in pregnancy initiated before 16 weeks of gestation to prevent preeclampsia."	3.91	Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. ( Grobman, W; Mallampati, D; Rouse, DJ; Werner, EF, 2019)
"Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders."	3.91	Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019)
"Women with lupus have an increased risk of preeclampsia and preterm birth, and aspirin 81 mg/day is recommended as a preventative measure for preeclampsia."	3.91	Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. ( Clowse, MEB; Eudy, AM; Myers, RA; Voora, D, 2019)
"There is recent evidence that prophylaxis with 150 mg of aspirin given before 14-16 weeks significantly reduces preeclampsia rates and may improve pregnancy outcome."	3.91	Impact of early supplementation with low-dose aspirin on functional first trimester parameters in low-risk pregnancies. ( Bot, M; Petca, A; Radu, D; Radu, N; Zvanca, ME, 2019)
"Low-dose aspirin started in early pregnancy significantly reduces the risk of preeclampsia (PE) in high-risk women, especially preterm PE."	3.88	Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study. ( Boutin, A; Bujold, E; Demers, S; Gasse, C; Giguère, Y; Tétu, A, 2018)
"To study women who initiated aspirin in the first trimester for high risk of pre-eclampsia, and compare blood-pressure trends throughout pregnancy between those with normal outcome and those who subsequently developed pre-eclampsia."	3.88	Maternal blood-pressure trends throughout pregnancy and development of pre-eclampsia in women receiving first-trimester aspirin prophylaxis. ( Baschat, AA; Blitzer, MG; Block-Abraham, D; Dewberry, D; Miller, JL; Seravalli, V, 2018)
"Low-dose aspirin is recommended for prevention of pre-eclampsia in high-risk pregnant women."	3.88	Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. ( Alfirevic, A; Alfirevic, Z; Jorgensen, A; Navaratnam, K, 2018)
"We sought to examine the effect of prophylactic use of aspirin during pregnancy in women at high risk of preeclampsia on length of stay in the neonatal intensive care unit."	3.88	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. ( de Alvarado, M; de Paco Matallana, C; Jani, JC; Machuca, M; Mastrodima, S; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tan, MY; Wright, D, 2018)
"To examine the effect of first-trimester screening for pre-eclampsia (PE) on the prediction of delivering a small-for-gestational-age (SGA) neonate and the effect of prophylactic use of aspirin on the prevention of SGA."	3.88	Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Greco, E; Janga, D; Jani, JC; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tan, MY; Wright, D, 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."	3.88	ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."	3.88	ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Aspirin use during pregnancy was associated with a reduced risk of hypoxia-related placental pathology in the high-risk population [the adjusted odds ratio and 95% confidence interval in the 1st, 2nd, and 3rd trimesters: 0."	3.88	Aspirin use during pregnancy and hypoxia-related placental pathology. ( Chen, C; Chen, Y; Feng, L; Ye, J; Ye, W; Zhang, J; Zhu, J; Zhu, X, 2018)
"The use of low-dose aspirin in pregnancy should remain a highly targeted indication since its long-term safety has not been established and should be restricted to women at high risk of vascular complications."	3.85	[For a targeted use of aspirin]. ( Brun, S; Coatleven, F; Gleyze, M; Lecoq, C; Madar, H; Merlot, B; Nithart, A; Sentilhes, L, 2017)
"The beneficial effect of aspirin in the prevention of preterm preeclampsia may not apply in pregnancies with chronic hypertension."	3.85	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. ( Akolekar, R; De Stefani, L; Delgado, JL; Evangelinakis, N; Gonzalez-Vanegas, O; Jani, JC; Leipold, G; Nicolaides, KH; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tsokaki, T; Wright, D, 2017)
"Low-dose aspirin has been demonstrated to reduce the incidence of preeclampsia and fetal growth restriction in at-risk populations."	3.85	Should we recommend universal aspirin for all pregnant women? ( McAuliffe, FM; McParland, P; Mone, F; Mulcahy, C, 2017)
" She was started on 100 mg of aspirin, 20 mg of prednisolone and 20 mg of subcutaneous low-molecular-weight heparin daily for her fourth pregnancy."	3.83	Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome: lessons learnt. ( Hui, CY; Tan, EL; Tan, LK; Tan, WC, 2016)
"To examine the effect of a combination of screening and treatment with low-dose aspirin on the prevalence of early-onset pre-eclampsia (PE)."	3.81	Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. ( Hyett, J; Leung, C; Ogle, R; Park, F; Pelosi, M; Puddephatt, R; Rawashdeh, H; Russo, K; Saaid, R; Walter, M; Williams, P, 2015)
" This study aims to investigate whether calcium channel blockers plus low dosage aspirin therapy can reduce the incidence of complications during pregnancy with chronic hypertension and improve the prognosis of neonates."	3.81	The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. ( Jiang, N; Liu, L; Liu, Q; Yang, WW; Zeng, Y, 2015)
"Evidence shows that daily low-dose aspirin during pregnancy can safely lower the risk of preeclampsia and other adverse outcomes."	3.81	Another good reason to recommend low-dose aspirin. ( Kirley, K; Oyola, S, 2015)
" Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy."	3.80	Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. ( LeFevre, ML, 2014)
"To identify patients at very high risk for adverse pregnancy outcome (APO) at the 20- to 23-week scan and to assess the effectiveness of Aspirin (ASS) and low molecular weight heparin (LMWH) starting after this examination."	3.79	Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects. ( Becker, R; Bittner, U; Fangerau, H; Keller, T; Kiesewetter, H, 2013)
"Aspirin treatment compared with untreated control groups led to a significant reduction of preeclampsia in 5 small-scale studies."	3.78	-Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies-. ( Lippert, TH; Mück, AO, 1996)
"In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")."	3.77	Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011)
"Verify that resistance to aspirin may have an impact on pregnancy and neonatal outcome."	3.77	Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011)
"The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders."	3.77	Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011)
"To evaluate the clinical and geographical variation in the use of aspirin in women at high risk of pre-eclampsia, and in the use of antihypertensive drugs and magnesium sulphate in women with established pre-eclampsia."	3.76	Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. ( Briley, AL; Chappell, LC; Enye, S; Poston, L; Seed, P; Shennan, AH, 2010)
" We present critical issues that need to be considered when evaluating and appraising test-treatment combinations, using the example of research on the uterine artery Doppler test to predict, and aspirin to prevent, pre-eclampsia."	3.76	How to interpret randomised trials of test-treatment combinations: a critical evaluation of research on uterine Doppler test to predict, and aspirin to prevent, pre-eclampsia. ( Coomarasamy, A; Fox, C; Khan, KS, 2010)
"5 of pregnancy, each group was respectively treated as follows: a) mice in group C (n = 12, control group) were injected with 100 microl of filtered phosphate-buffered saline into the tail vein every day; b) group PE (n = 15, preeclampsia model group) were injected in the same way with 100 microl of filtered PS/PC vesicle suspension; c) group H (n = 9, group treated with heparin) were injected with 1 unit heparin together with PS/PC vesicle suspension; d) group A (n = 10, group treated with aspirin) were injected with 20 microg/g aspirin-DL lysine as well; e) group LD (n = 10, group treated with low-dose Danshensu) were injected with 10 microg/g Danshensu; and f) group HD (n = 10, group treated with high-dose Danshensu) were injected with 30 microg/g Danshensu."	3.76	Effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine microvesicle induced-mouse model: is it a candidate for preeclampsia remedy? ( Hu, YL; Shen, Y; Wang, JM; Zhang, Y, 2010)
"Treatment of preeclampsia with prostacyclin appears to be contraindicated because prostacyclin is a potent systemic vasodilator and the clinical outcome of preeclamptic women infused with prostacyclin has been poor."	3.76	Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia. ( Walsh, SW, 1989)
"Two meta-analyses suggest that low-dose aspirin taken daily during pregnancy reduces the incidence of pre-eclampsia in women at risk and reduces mortality among the infants born to mothers at high risk of pre-eclampsia."	3.75	Pre-eclampsia: aspirin beneficial. ( , 2009)
" With a treatment that included aspirin, heparin, and a nitric oxide donor, her third pregnancy ended with a healthy neonate at term."	3.74	Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma. ( Cabane, J; Carbonne, B; Cynober, E; Macé, G; Milliez, J, 2007)
"To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia."	3.74	Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007)
"Our results reaffirm previous reports that the use of LMWH in combination with low dose aspirin throughout pregnancy is safe and effective."	3.73	Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology. ( Delkos, D; Giannoulis, H; Gkoutzioulis, F; Kalogiros, G; Papaloukas, C; Petropoulos, P; Psarra, A; Tzafettas, J, 2005)
"To elucidate the efficacy of the treatment using a Japanese-modified Chinese herbal medicine, Sairei-to, and low-dose aspirin with or without a corticosteroid hormone for the patients with adverse pregnancy histories positive for anti-phospholipid antibodies."	3.73	Prophylactic therapy for patients with reproductive failure who were positive for anti-phospholipid antibodies. ( Ishii, K; Kikuchi, A; Nonaka, T; Ooki, I; Takakuwa, K; Tamura, M; Tamura, N; Tanaka, K, 2006)
"The prevention of preeclampsia currently relies on low-dose aspirin started at the beginning of pregnancy."	3.72	[Prevention of preeclampsia]. ( Desvaux, D; Haddad, B, 2003)
" If thrombophilia was diagnosed on the basis of hyperhomocysteinemia, the treatment consisted of aspirin, pyridoxine and folic acid, instead."	3.71	Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. ( Aardenburg, R; de Leeuw, PW; Ekhart, TH; Peeters, LL; Spaanderman, ME; van der Heijden, OW; van Eyck, J; van Eyndhoven, HW, 2001)
"To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome."	3.70	Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998)
"To our knowledge, this is the first time that a combination of aspirin and glyceryl trinitrate (GTN) has been used in the prophylaxis of preeclampsia and fetal growth retardation, and their use associated with not only Doppler screening of the uterine arteries but also regular Doppler follow-up of the fetal arterial and venous circulation."	3.70	A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth. ( Black, RS; Campbell, S; Lees, CC; Oyelese, KO, 1998)
" The success rate was higher when treatment was given because of previous poor pregnancy outcomes than when it was given for other indications, and the patients with successful therapy had started aspirin earlier than had those with therapy failure (17."	3.70	Effect of aspirin in pregnant women is dependent on increase in bleeding time. ( Beaufils, M; Dumont, A; Flahault, A; Uzan, S; Verdy, E, 1999)
"Despite optimism generated by earlier, smaller studies, the Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) trial showed that aspirin is not sufficiently effective to recommend its widespread use for the prevention of pre-eclampsia."	3.69	Pre-eclampsia. III: The role of aspirin in prevention. ( de Swiet, M, 1994)
"To determine if low dose aspirin therapy improves placental histology in women with a prior complicated pregnancy demonstrating uterine vascular pathology."	3.69	Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. ( Campbell, WA; Cusick, W; Ernst, L; Rodis, JF; Salafia, CM; Vintzileos, AM, 1995)
" Magnesium and dihydralazine effects in pregnancy are not related to altered release of trophoblast vasoactive compounds."	3.69	Drug actions in preeclampsia: aspirin, but not magnesium chloride or dihydralazine, differentially inhibits cultured human trophoblast release of thromboxane and prostacyclin without affecting angiotensin II, endothelin-1, or leukotriene B4 secretion. ( Cervar, M; Desoye, G; Kainer, F; Nelson, DM, 1997)
"To describe patterns of prescription in the Netherlands of low-dose aspirin in pregnancy."	3.68	Low-dose aspirin in pregnancy: changes in patterns of prescription in The Netherlands. ( Bremer, HA; Wallenburg, HC, 1993)
"To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation."	3.68	Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993)
" Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established."	3.68	[A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992)
"Low-dose Aspirin inhibits thromboxane A2 with minimal effects on prostacyclin and induces clinical improvements in pre-eclampsia."	3.68	Treatment of severe pre-eclampsia by acetyl salicylic acid. ( Abd-Rabbo, S; Khowessah, M; Shaala, S; Toppozada, M; Zoheir, A, 1991)
"Pregnancy-induced hypertension (PIH) and preeclampsia develop when an imbalance occurs between prostacyclin (PGI2) and thromboxane A2 (TXA2) production."	3.68	[Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of its therapeutic effect]. ( Iwata, I; Iwata, M; Masuhiro, K; Mitsuda, N; Nishino, E; Takagi, T; Tanizawa, O, 1990)
" Despite preeclampsia our patient successfully completed her 6th pregnancy after treatment with corticosteroids, subcutaneous heparin, and low dose aspirin throughout the pregnancy."	3.67	Subclinical autoimmune disease and recurrent spontaneous abortion. ( Andreoli, J; Hakim, C; Maier, D; Parke, A; Randolph, J, 1986)
"Pregnant women with either Type B EPH gestosis or gestosis alone were treated with low dose aspirin if thrombocytopenia were present (platelet counts below 75,000) or had platelet aggregation studies if their platelet counts were above 75,000."	3.66	Diagnosis and treatment of pregnancy induced platelet dysfunction. ( Davis, RB; Goodlin, RC, 1983)
"In four patients with clinical and laboratory manifestations of the hemolytic-uremic syndrome, the administration of aspirin and dipyridamole was associated with a dramatic and rapid increase in the platelet count."	3.66	The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function. ( Carone, FA; Green, D; Rossi, EC; Thorsen, CA, 1979)
"The incidence of preterm preeclampsia was 1."	3.30	Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023)
"The main outcome was preeclampsia or a birthweight ≤ 5th percentile."	3.11	Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial. ( Arthuis, C; Cheve, MT; Debarge, VH; Delmas, HL; Diguisto, C; Doret, M; Durin, L; Equy, V; Flandrin, A; Gallot, D; Giraudeau, B; Haddad, G; Le Gouge, A; Marchand, MS; Mares, P; Megier, P; Paumier, A; Perrotin, F; Schaub, B; Sentilhes, L; Vayssiere, C; Ville, Y; Winer, N, 2022)
"A dosage of 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation, did not reduce the incidence of preeclampsia in pregnant women with high-risk factors in China."	3.11	A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. ( Chen, D; Chen, J; Cui, S; Ding, H; Huai, J; Juan, J; Li, B; Li, G; Li, X; Lin, L; Ma, Y; Mi, Y; Qi, H; Sun, X; Yang, H; Yu, M; Zhang, H; Zhang, M; Zhang, W; Zhao, X; Zhao, Y; Zhu, Y, 2022)
"Preeclampsia is a hypertensive disorder of pregnancy affecting up to 8% of pregnancies."	3.01	Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy. ( Costantine, MM; Eid, J; Rood, KM, 2023)
"Aspirin was not found to substantially diminish the risk of incidence of preeclampsia, but it did show some beneficial effects."	3.01	Role of aspirin in the prevention of preeclampsia in previously hypertensive pregnant women: A Meta-Analysis. ( Ashraf Jahangeer, SM; Khan, AA; Mansoor, M, 2023)
"Preeclampsia and gestational hypertension are common pregnancy complications associated with adverse maternal and child outcomes."	3.01	Polygenic prediction of preeclampsia and gestational hypertension. ( Antopia, MC; Bhatta, L; Brumpton, BM; Cho, SMJ; Do, R; Gray, KJ; Guerrero, RF; Gupta, RM; Haas, DM; Honigberg, MC; Khan, RR; Koyama, S; Laisk, T; Martin, HC; Nadkarni, GN; Natarajan, P; Patel, AP; Patil, S; Pe'er, I; Saxena, R; Schuermans, A; Selvaraj, MS; Trinder, M; Truong, B; Urbut, SM; van Heel, DA; Vellarikkal, SK; Verma, SS; Vy, HMT; Xiao, B; Yan, Q; Zöllner, S, 2023)
"ASA use during pregnancy has benefits beyond reducing the risk of pre-eclampsia."	3.01	The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth. ( Berger, R; Hinz, B; Stubert, J, 2023)
"Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR)."	3.01	Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol). ( Adeyemo, TA; Afolabi, BB; Babah, OA; Ezeaka, CV; Nwaiwu, O; Odukoya, OO; Ogunnaike, BA; Oshodi, YA, 2021)
"Preeclampsia and gestational hypertension are common complications of pregnancy associated with significant maternal and infant morbidity."	2.94	Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension. ( Andriessen, VC; Connell, M; Kim, K; Mendola, P; Mumford, SL; Nobles, CJ; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L, 2020)
"The risk of preeclampsia was not different when comparing the aspirin and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and race groups."	2.94	Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. ( Aagaard, KM; Mendez-Figueroa, H; Sangi-Haghpeykar, H; Tolcher, MC, 2020)
"The Aspirin for Evidence-Based Preeclampsia Prevention trial data are consistent with the hypothesis that aspirin delays the gestational age at delivery with preeclampsia."	2.90	Aspirin delays the development of preeclampsia. ( Nicolaides, KH; Wright, D, 2019)
"Among women receiving placebo, preeclampsia occurred significantly more often in women with stage 1 hypertension compared with normotensive high-risk women after adjustment for maternal age and body mass index (39."	2.87	Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. ( Caritis, SN; Catov, JM; Hauspurg, A; Sutton, EF, 2018)
"When aspirin was initiated at > 16 weeks, with a dosage of < 100 mg/day aspirin, there was a lesser preventive effect (RR = 0."	2.82	The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. ( Dai, C; He, Q; Huang, X; Lee, W; Li, L; Li, R; Luo, Z; Mok, TN; Yip, KC; Zeng, W, 2022)
"Two proteases that are elevated in preeclampsia and activate protease-activated receptor 1 are matrix metalloproteinase-1 and neutrophil elastase."	2.82	Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia? ( Strauss, JF; Walsh, SW, 2022)
"Given the burden of preeclampsia, the identification of women at high risk in early pregnancy is essential to allow for preventive strategies and close monitoring."	2.82	Screening for preeclampsia in twin pregnancies. ( Francisco, C; Gamito, M; Reddy, M; Rolnik, DL, 2022)
"Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth."	2.82	The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022)
"It has been reported that preeclampsia initiates from a mismatch between the utero-placental supply and demand, which subsequently triggers the release of placental syncytiotrophoblast stress-derived factors and an imbalance of proangiogenic/antiangiogenic factors, eventually causing maternal systemic endothelial lesions and systemic inflammatory response."	2.82	[Latest Findings on Prediction and Prevention of Preeclampsia]. ( Li, XT; Xiao, XR; Xiong, Y; Ye, YZ; Zhou, QJ, 2022)
"In addition, treating chronic hypertension neither reduces nor increases fetal or newborn death or morbidity, regardless of the gestational age at which the antihypertensive treatment is started."	2.82	Toward personalized management of chronic hypertension in pregnancy. ( Kametas, N; Khalil, A; Magee, LA; von Dadelszen, P, 2022)
" These inconsistencies, however, can be largely explained by a high degree of heterogeneity regarding the selection of trial participants, baseline risk of the included women, dosage of aspirin, gestational age of prophylaxis initiation, and preeclampsia definition."	2.82	Prevention of preeclampsia with aspirin. ( Nicolaides, KH; Poon, LC; Rolnik, DL, 2022)
"When superimposed preeclampsia was present, it developed at an earlier gestational age among the group without GDM (35 ± 5 vs."	2.82	Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension. ( Blackwell, SC; Haidar, ZA; Leon, MG; Longo, M; Mendez-Figueroa, H; Moussa, HN; Pedroza, C; Sibai, BM, 2016)
"Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17."	2.80	Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Post, AL, 2015)
"Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation."	2.79	Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014)
"The rate of superimposed preeclampsia was 28."	2.79	Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial. ( Atallah, AN; Kulay, L; Santos, GM; Sass, N; Souza, EV; Torloni, MR, 2014)
"Development of preeclampsia can be decreased by prescribing low-dose aspirin to high-risk women."	2.72	Family History of Hypertension, Cardiovascular Disease, or Diabetes and Risk of Developing Preeclampsia: A Systematic Review. ( Kay, VR; Smith, GN; Wedel, N, 2021)
"Hemorrhagic stroke is the most common type of obstetric stroke."	2.72	Stroke in Pregnancy: A Multidisciplinary Approach. ( Camargo, EC; Singhal, AB, 2021)
"In preterm preeclampsia, women assigned at random to 150 mg experienced a significant 62% reduction in risk of preterm preeclampsia (RR = 0."	2.72	Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis. ( Flyke, IP; Hennekens, CH; Hoppe, KK; Kim, K; Lasarev, M; Mukhtarova, N; Van Doorn, R, 2021)
"Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking."	2.72	Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021)
"It was effective in reducing preterm preeclampsia, but not term preeclampsia, and patient compliance and patient weight were important variables."	2.72	The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta. ( Strauss, JF; Walsh, SW, 2021)
"Salicylic acid was detected in 1 infant only."	2.71	Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. ( Bernert, S; Leonhardt, A; Schmitz-Ziegler, G; Seyberth, HW; Watzer, B, 2003)
"The trial enrolled 139 women at risk of preeclampsia or IUGR, with abnormal uterine artery Doppler findings that included the presence of unilateral or bilateral diastolic notch, high resistance index (RI), or high pulsatility index (PI) at 14-16 weeks of gestation."	2.71	Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. ( Ebrashy, A; Ibrahim, M; Marzook, A; Yousef, D, 2005)
"The reduction in the incidence of intrauterine growth retardation (2."	2.70	Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. ( Iso-Mustajärvi, M; Kujansuu, E; Mäenpää, J; Vainio, M, 2002)
"Whether low-dose aspirin prevents preeclampsia is unclear."	2.69	Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998)
"Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery."	2.67	CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994)
"To assess its efficacy in preventing preeclampsia, 60 mg/day aspirin or a matching placebo was administered to women in a double-blind fashion during the second and third trimesters."	2.67	Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. ( Arheart, KL; Di Sessa, TG; Khoury, A; Moretti, ML; Pulliam, DA; Sibai, BM, 1994)
"Aspirin treatment did not affect the relation between the Doppler indices and these outcomes in the logistic regression model."	2.67	The predictive value of umbilical artery Doppler studies for preeclampsia or fetal growth retardation in a preeclampsia prevention trial. ( Atkinson, MW; Copper, RL; Goldenberg, RL; Hauth, JC; Maher, JE; Owen, J, 1994)
"The occurrences of IUGR and preeclampsia in the study group (7."	2.67	[Prevention of fetal growth retardation by low dose aspirin]. ( Li, WJ; Wang, ZH, 1993)
"The incidence of preeclampsia was lower in the aspirin group (69 of 1485 women [4."	2.67	Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, SN; Klebanoff, M; McNellis, D; Paul, RH; Rocco, L; Romero, R; Rosen, M; Sibai, BM; Thom, E; Witter, F, 1993)
"Preeclampsia affects up to 8% of pregnancies worldwide and remains a major cause of maternal and neonatal morbidity and mortality."	2.66	Novel Interventions for the Prevention of Preeclampsia. ( Costantine, MM; Kniss, D; Ma'ayeh, M; Rood, KM, 2020)
"Preeclampsia is considered a specific disease of pregnancy, but recent theories suggest that women suffering from the condition have greater propensity to develop atherosclerosis, heart disease, and stroke over the years."	2.66	Analyzing Preeclampsia as the Tip of the Iceberg Represented by Women with Long-Term Cardiovascular Disease, Atherosclerosis, and Inflammation. ( Diniz, AD; Diniz, ALD; Paes, MMBM, 2020)
"Preeclampsia is an obstetric disorder that affects 3-8% of pregnant women and remains a leading cause of short- and long-term neonatal and maternal morbidity and mortality."	2.66	Prevention of preeclampsia. ( Costantine, MM; Ma'ayeh, M, 2020)
"Chronic hypertension affects 1-5% of women of childbearing age."	2.66	Aspirin for the prevention of placenta-mediated complications in pregnant women with chronic hypertension. ( Haddad, B; Lecarpentier, E, 2020)
"Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system."	2.66	Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020)
"Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss."	2.66	Understanding and Preventing Placenta-Mediated Pregnancy Complications. ( Blondon, M; Ní Áinle, F; Skeith, L, 2020)
"Although migraine improves or disappears during pregnancy, a significant association between migraine and hypertension (i."	2.66	The Potential Protective Role of Aspirin Against Migraine in Pregnant Women. ( Gong, Y; Liu, X, 2020)
"Women with chronic hypertension have a higher incidence of superimposed preeclampsia, cesarean section, preterm delivery before 37 weeks' gestation, birth weight less than 2500 g, neonatal unit admission, and perinatal death."	2.66	Hypertension During Pregnancy. ( Agrawal, A; Wenger, NK, 2020)
"Preeclampsia is a complex disease affecting 2-8% of pregnancies worldwide."	2.66	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. ( Beard, S; Binder, NK; Brownfoot, F; de Alwis, N; Hannan, NJ; Kaitu'u-Lino, TJ; Tong, S, 2020)
"The pregnancy was normal in 54% of patients in group A and 23% in group B (p less than 0."	2.65	[Controlled trial of preventive treatment of preeclampsia. Preliminary results]. ( Beaufils, M; Colau, JC; Donsimoni, R; Uzan, S, 1984)
"Methods, results: Preeclampsia (PE) is a multisystem disorder complicating pregnancy."	2.61	First-trimester screening for preeclampsia. ( Feyereisl, J; Krofta, L; Lošan, P; Lubušký, M; Marková, I; Pilka, R; Roubalová, L; Skřivánek, A; Vojtěch, J, 2019)
"Compared with control intervention for recurrent miscarriage, enoxaparin treatment has no substantial influence on live births (RR = 1."	2.61	Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studies. ( Chen, Y; Cheng, X; Li, N; Lin, T; Sheng, X, 2019)
"Angiogenic and non-angiogenic preeclampsia are identified by a sFlt-1PlGF≥85 and<85, respectively, with the risk of maternal and fetal complications at two weeks differing between the two."	2.61	[Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians]. ( Achiche, J; Ahriz Saksi, S; Bailleul, S; Boulanger, H; Drouin, D; Dupuis, E; Ekoukou, D; Lefèvre, G; Sault, C; Stawiarski, N, 2019)
"Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality."	2.61	Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019)
" Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered."	2.61	Chronic Kidney Disease and Pregnancy. ( Hladunewich, MA; Hui, D, 2019)
"Preterm preeclampsia (PE), occurring at < 37 weeks' gestation, can be predicted from as early as 11-13 weeks and prevented with the use of aspirin."	2.58	Prediction of preeclampsia developing at term. ( Huluta, I; Panaitescu, AM, 2018)
"It has been now widely accepted that preeclampsia is most a systemic inflammatory and systemic vascular disease during pregnancy and then a lifelong risk factor for subsequent cardiovascular event in women's life."	2.58	[Preeclampsia: A challenge also for cardiologists]. ( Cournot, M; Lairez, O; Medzech, B, 2018)
"Aspirin has proved its efficacy in primary and secondary pre-eclampsia prevention, especially when it is given at 150mg per day bedtime before 15 weeks of gestation to high-risk women."	2.58	[Pre-eclampsia prevention in 2018 in general population and in lupic women: At the dawn of a personalized medicine?] ( de Moreuil, C; Fauchais, AL; Lacut, K; Le Moigne, E; Merviel, P; Pan-Petesch, B; Pasquier, E; Tremouilhac, C, 2018)
" Screening modalities, target population, and aspirin dosage are still a matter of debate."	2.55	Aspirin for Prevention of Preeclampsia. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2017)
"Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin."	2.55	[Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017)
"Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation."	2.55	Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. ( Askie, L; Duley, L; Hunter, K; Meher, S, 2017)
"Spontaneous preterm birth is an important cause of neonatal mortality and morbidity."	2.55	Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis. ( Askie, LA; Mol, BWJ; Oudijk, MA; van Vliet, EOG, 2017)
"Outcomes included preeclampsia (mild and severe) and SGA neonates."	2.53	Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Outcomes included preeclampsia, severe preeclampsia, and SGA."	2.53	Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Today, pregnancy is no longer considered impossible in women with lupus."	2.53	Pregnancy in women with systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2016)
"Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide."	2.53	Aspirin vs Heparin for the Prevention of Preeclampsia. ( Kanellopoulou, T; Katsi, V; Makris, T; Nihoyannopoulos, P; Nomikou, E; Tousoulis, D, 2016)
"Low-dose aspirin significantly reduced preeclampsia risk in both East Asians (OR = 0."	2.53	Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians:A systematic review and meta-analysis. ( Gan, J; He, H; Qi, H, 2016)
"Worldwide, preeclampsia is a significant health risk to both pregnant women and their unborn children."	2.52	Immunomodulatory role of vitamin D in the pathogenesis of preeclampsia. ( Agrawal, DK; Kirkpatrick, DR; Kovilam, O; Smith, TA, 2015)
" Careful attention must be paid to the dosing and potential teratogenicity of medications."	2.52	Pregnancy and Lupus Nephritis. ( Garovic, VD; Kattah, AG, 2015)
"For the prevention of preeclampsia, it is worth considering for women who are at high risk of developing the disease."	2.50	[Acetylsalicylic acid and prevention of preeclampsia]. ( Kajantie, E; Laivuori, H; Villa, PM, 2014)
"Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality."	2.50	Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014)
"Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality."	2.50	Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014)
"The outcomes of interest were preterm preeclampsia (delivery <37 weeks) and term preeclampsia."	2.48	Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. ( Bakthi, A; Bujold, E; Ebrashy, A; Giguère, Y; Nicolaides, K; Roberge, S; Vainio, M; Villa, P, 2012)
"The outcomes of interest were severe preeclampsia and mild preeclampsia."	2.48	Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. ( Bujold, E; Forest, JC; Giguère, Y; Nicolaides, K; Roberge, S; Tapp, S; Vaiman, D; Vainio, M; Villa, P; von Dadelszen, P; von Dadelzen, P, 2012)
"Women treated for preeclampsia also have an increased risk for cardiovascular and renal disease."	2.48	Preeclampsia 2012. ( Eiland, E; Faulkner, M; Nzerue, C, 2012)
"Careful counseling of women with diabetic nephropathy before pregnancy with estimation of the risk for the mother and fetus is important."	2.48	Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. ( Clausen, P; Damm, P; Feldt-Rasmussen, B; Mathiesen, ER; Ringholm, L, 2012)
"Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit."	2.47	Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011)
"Obstetric antiphospholipid antibody syndrome (APS) is diagnosed in the presence of certain clinical features in conjunction with positive laboratory findings."	2.47	Obstetric antiphospholipid syndrome: an update on pathophysiology and management. ( Ernest, JM; Kutteh, WH; Marshburn, PB, 2011)
"Aspirin has shown efficacy in preventing PE with a 10 % incidence reduction."	2.46	[Prevention of preeclampsia]. ( Coutty, N; Deruelle, P; Girard, JM; Subtil, D, 2010)
"The primary outcome was preeclampsia."	2.45	Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. ( Bujold, E; Forest, JC; Giguère, Y; Lacasse, Y; Morency, AM; Roberge, S, 2009)
"Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies."	2.44	Prediction and prevention of recurrent preeclampsia. ( Barton, JR; Sibai, BM, 2008)
"Antiphospholipid syndrome is one of the few treatable causes of pregnancy loss, and successful pregnancy rates of 70% or more can be achieved with appropriate treatment."	2.44	[Pregnancy and antiphospholipid antibodies]. ( Goffinet, F; Le Guern, V, 2008)
"The pathophysiology of preeclampsia is still unknown."	2.44	[Prophylactic treatment of preeclampsia]. ( Abele, H; Bohlmann, MK; Schauf, B; Wallwiener, D, 2007)
"Preventive treatment of preeclampsia consists essentially of low dose aspirin."	2.44	[Latest developments: management and treatment of preeclampsia]. ( Tsasaris, V; Winer, N, 2008)
"Aspirin has potential risks."	2.44	Aspirin and reproductive outcomes. ( Brancazio, LR; James, AH; Price, T, 2008)
"Preeclampsia is a pregnancy-associated illness affecting multiple organ systems."	2.44	[Anesthetic management of parturients with pre-eclampsia and eclampsia]. ( Bremerich, DH; Fetsch, NI, 2008)
"Preeclampsia is accompanied by high fetal and maternal morbidity and mortality and to a high degree responsible for preterm delivery."	2.43	[Prevention of preeclampsia]. ( Diedrich, F; Fischer, T; Jacobs, VR; Neumaier-Wagner, P; Paepke, S; Pildner von Steinburg, S; Schneider, KT, 2005)
"The incidence of preeclampsia was 3."	2.43	Prevention of preeclampsia with low-dose aspirin -- a systematic review and meta-analysis of the main randomized controlled trials. ( Fontes, RS; Ruano, R; Zugaib, M, 2005)
"Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment."	2.43	Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006)
"Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well."	2.42	[Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003)
"Aspirin was also associated with a reduction in rates of spontaneous preterm birth (OR 0."	2.42	Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. ( Coomarasamy, A; Gee, H; Honest, H; Khan, KS; Papaioannou, S, 2003)
"The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients."	2.42	Antiphospholipid syndrome in obstetrics. ( Heilmann, L; Pollow, K; von Tempelhoff, GF, 2003)
"Preeclampsia is a multisystem disorder that complicates 6% to 8% of pregnancies, with higher rates in women with preexisting hypertension, diabetes mellitus, or previous history of preeclampsia."	2.42	What we have learned about preeclampsia. ( Caritis, S; Hauth, J; Sibai, BM, 2003)
"Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition."	2.42	[Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003)
"Preeclampsia is characterized by an imbalance between two cyclooxygenase metabolites of arachidonic acid, thromboxane and prostacyclin, that favors thromboxane."	2.42	Eicosanoids in preeclampsia. ( Walsh, SW, 2004)
"Preeclampsia is characterized by hypertension and proteinuria."	2.42	Pathophysiology of preeclampsia: links with implantation disorders. ( Beaufils, M; Carbillon, L; Challier, JC; Merviel, P; Rabreau, M; Uzan, S, 2004)
" Discrepancies seem largely related to either studying very low-risk populations, or strong differences in aspirin dosage and/or term of introduction."	2.41	[Aspirin and prevention of pre-eclampsia]. ( Beaufils, M, 2000)
"If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved."	2.41	A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001)
"The baseline risk of preeclampsia in women with abnormal uterine artery Doppler was 16%, and the number of women needed to be treated with aspirin to prevent one case of preeclampsia was 16 (95% CI 8, 316)."	2.41	Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. ( Coomarasamy, A; Gee, H; Khan, KS; Papaioannou, S, 2001)
"Normal pregnancy is characterized by a marked reduction in peripheral vascular resistance."	2.40	Hypertension in pregnancy. ( Bernheim, J, 1997)
"Until the pathogenesis of preeclampsia is well defined, prevention of this syndrome with any modality remains unlikely."	2.40	Prevention of preeclampsia: a big disappointment. ( Sibai, BM, 1998)
"Myocardial infarction is rare in pregnancy."	2.39	Myocardial infarction in a parturient. A case report with emphasis on medication and management. ( Haring, P; Hietakorpi, S; Koski, E; Nuutinen, LS; Purhonen, S; Söderlin, MK, 1994)
"Early-onset preeclampsia appears to be associated with certain disorders that are likely to provoke an arterial thrombotic process by impairing the normal endothelial cell-platelet interactions."	2.39	Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. ( Dekker, GA; van Geijn, HP, 1996)
"Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)."	2.39	Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996)
"Preeclampsia is characterized by a functional imbalance between vascular prostacyclin and thromboxane A2 production."	2.38	[Acetylsalicylic acid in pregnancy]. ( Egarter, C; Husslein, P; Karas, H, 1993)
"On the basis of the hypothesis that preeclampsia is at least partially caused by an increase in thromboxane A2, some studies attempted to correct this pathologic condition by pharmacologic manipulation with low-dose aspirin."	2.38	Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. ( Dekker, GA; Sibai, BM, 1993)
"The characteristics and treatment of preeclampsia and eclampsia are reviewed."	2.38	Treatment of preeclampsia and eclampsia. ( McCombs, J, 1992)
"Preeclampsia is a syndrome of unknown etiology characterized by the sequential development of facial and hand edema, hypertension, and proteinuria after the 20th week of gestation."	2.38	New concepts in the understanding of hypertensive diseases during pregnancy. An overview. ( Zuspan, FP, 1991)
"Preeclampsia is a disease unique to pregnancy."	2.38	Prevention of preeclampsia. ( Repke, JT, 1991)
" Clinicians who decide to manage complicated or potentially complicated patients with chronic administration of aspirin must continue to study these mothers, fetuses, and neonates intensively and to document their results."	2.38	Low-dose aspirin to improve perinatal outcome. ( Barton, JR; Sibai, BM, 1991)
"To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients."	1.91	Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression of ATF2. ( Guo, L; Hu, R; Liu, R; Xiao, S; Zhang, M, 2023)
"Risk for preterm preeclampsia (<37 weeks) was calculated using the Fetal Medicine Foundation algorithm, and individuals with a risk score ≥1 per 100 were recommended to use aspirin (162 mg once daily at bedtime, <16-36 weeks)."	1.91	The Implementation of Preeclampsia Screening and Prevention (IMPRESS) Study. ( Chada, R; Dwinnell, SJ; Johnson, DW; Johnson, JM; Kuret, VH; Mahallati, H; Maxey, CM; Metcalfe, A; Nerenberg, KA; O'Quinn, CP; Okun, NB; Pastuck, ML; Paterson, K; Paul, H; Schacher, J; Silang, KA; Soliman, N; Somerset, DA; Suchet, IB; Walsh, JD, 2023)
" In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR = 7."	1.91	Management and outcomes of women with antiphospholipid syndrome during pregnancy. ( Adurty, S; D'Angelo, D; DeSancho, MT; Tao, JJ, 2023)
"Treatment with aspirin during pregnancy was also recorded."	1.91	Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain. ( Adiego, B; Carrillo, MP; Cuenca-Gómez, D; de Paco Matallana, C; Delgado, JL; Gil, MM; Mendoza, M; Molina, FS; Revello, R; Rolle, V; Santacruz, B; Valiño, N; Wright, A, 2023)
" The Royal College of Obstetricians and Gynaecologists recommends 150 mg of aspirin daily, and the National Institute of Health and Care Excellence guidelines suggest risk stratification with a dosage of 75 mg for those at moderate risk of preeclampsia and 150 mg for those at high risk of preeclampsia."	1.91	Low-dose aspirin therapy for the prevention of preeclampsia: time to reconsider our recommendations? ( Abuhamad, A; Hage Diab, Y; Horgan, R; Saade, G; Waller, J, 2023)
"Preeclampsia is a multisystemic disorder of pregnancy that affects 250,000 pregnant individuals in the United States and approximately 10 million worldwide per annum."	1.91	Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. ( Barton, JR; Beck, S; Bernstein, IM; Buck, TE; Facco, FL; Forgues-Lackie, MA; Gernand, AD; Graves, CR; Hauspurg, A; Jeyabalan, A; King, TL; Manuck, TA; Myatt, L; Myers, JE; Powell, TM; Roberts, JM; Sutton, EF; Tinker, E; Tsigas, E, 2023)
"Fifteen (1."	1.91	Implementing Preeclampsia Screening in Switzerland (IPSISS): First Results from a Multicentre Registry. ( Amylidi-Mohr, S; Ardabili, S; Challande, P; Hodel, M; Hösli, I; Kohl, J; Manegold-Brauer, G; Mosimann, B; Raio, L; Schönberger, H; Surbek, D; Trottmann, F, 2023)
"The risk of preterm preeclampsia (PT PE) can significantly be reduced by starting acetylsalicylic acid ≤ 16 weeks of gestational age."	1.91	Cost-effectiveness analysis of a first-trimester screening test for preterm preeclampsia in the Netherlands. ( Beernink, RHJ; Cremers, TIFH; Scherjon, SA; van Asselt, ADI, 2023)
"Documentation of preeclampsia risk factors: multifetal gestation, pregestational diabetes, chronic hypertension (high-risk factors) and nulliparity, a body mass index greater than 30, African American race, a maternal age 35 years or older, an interval of more than 10-years since last birth, and having low socioeconomic status (moderate risk factors)."	1.72	Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019. ( Myers, ER; Myers, SO; Swamy, GK; Wheeler, SM, 2022)
"Low-dose aspirin for preeclampsia is routinely used."	1.72	Antepartum Care of the Uterus Transplant Patient: The Experience of 3 Successful US Centers. ( Gregg, AR; Perni, UC; Wang, EY, 2022)
"Analyze secular trends of preeclampsia in Norway based on risk factors."	1.72	Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway. ( Laine, K; Räisänen, S; Sole, KB; Staff, AC, 2022)
"Evidence on the risk of preterm preeclampsia was taken from the Screening programme for pre-eclampsia study, which was a first-trimester screening study for the prediction of preeclampsia."	1.72	When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. ( Nicolaides, KH; Tan, MY; Wright, A; Wright, D, 2022)
"Recurrent preeclampsia occurred in 467 (45."	1.72	Patient-reported preconceptional characteristics in the prediction of recurrent preeclampsia. ( Bijl, RC; Brewer, AN; Cornette, JMJ; Franx, A; Koster, MPH; Tsigas, EZ; Zwart, IF, 2022)
"Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality."	1.72	Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022)
"To evaluate the effectiveness of a preeclampsia (PE) screening program using the National Institute for Health and Care Excellence (NICE) guideline in pregnant Thai women."	1.72	Low-dose aspirin for prevention of preeclampsia: Implementation of the NICE guideline in Thailand. ( Charernjiratragul, K; Geater, A; Khwankaew, N; Suksai, M; Suntharasaj, T; Suwanrath, C, 2022)
"Reportedly, aspirin prevents preeclampsia, specifically early-onset preeclampsia, although findings in decidual arteries in women treated with aspirin therapy remain unclear."	1.72	Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia. ( Gi, T; Katsuragi, S; Kodama, Y; Maekawa, K; Sameshima, H; Sato, Y; Tomimori-Gi, K; Yamada, N; Yamashita, A, 2022)
"Aspirin use was recommended for cases who were at high risk of preterm PE."	1.72	Machine-learning-based prediction of pre-eclampsia using first-trimester maternal characteristics and biomarkers. ( Ansbacher-Feldman, Z; Cirkin, R; Louzoun, Y; Meiri, H; Nicolaides, KH; Syngelaki, A, 2022)
"· High-risk patients who lack a history preeclampsia were less likely to be advised of aspirin use."	1.62	Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. ( Berghella, V; Boelig, RC; Roman, A; Wanees, M; Zhan, T, 2021)
"Our laboratory demonstrated that preeclampsia is associated with high soluble fms-like tyrosine kinase 1 (sFlt-1) and low heme oxygenase-1 (HO1/Hmox1) expression."	1.62	MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment. ( Agrawal, S; Ahmad, S; Ahmed, A; Alzahrani, FA; Dias, IH; Rezai, H; Sanchez-Aranguren, L; Sparatore, A; Wang, K, 2021)
"Human pregnancy is associated with a mild proinflammatory state characterized by circulatory neutrophil activation which is further increased in complicated pregnancies, placenta-mediated complications being associated with an increased thrombotic risk."	1.62	NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes. ( Bouvier, S; Demattei, C; Fortier, M; Gris, JC; Herzog, M; Letouzey, V; Mercier, E; Mousty, E; Nouvellon, E; Rommelaere, G; Vincent, L, 2021)
"Preeclampsia is a severe gestational hypertensive disorder that occurs after 20 weeks' of gestation."	1.62	Aspirin facilitates trophoblast invasion and epithelial-mesenchymal transition by regulating the miR-200-ZEB1 axis in preeclampsia. ( Kuo, PL; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2021)
"Aspirin-prophylaxis was administered either in 100 mg (n = 229) or 150 mg (n = 90) daily."	1.62	Low Dose Aspirin in high-risk pregnancies: The volatile effect of acetylsalicylic acid on the inhibition of platelets uncovered by G. Born's light transmission aggregometry. ( Cervar-Zivkovic, M; Eberhard, K; Kutllovci-Hasani, K; Mayer-Pickel, K; Nanda, M; Prüller, F; Stern, C; Weiss, EC, 2021)
"The new pyramid of pregnancy care integrates an early clinic allowing the assessment of biophysical and biochemical markers combined with maternal factors."	1.62	Practical approach to the prevention of preeclampsia: from screening to pharmaceutical intervention. ( Ahmed, B; Ayoubi, JM; Rafii Tabrizi, A, 2021)
"Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis."	1.56	Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. ( Afshar, Y; Bromley, B; Caughey, AB; Chescheir, N; Copel, JA; Grechukhina, O; Grobman, W; Han, CS; Hobbins, JC; Mallampati, D; Nicolaides, K; Pettker, C; Platt, LD; Saade, G; Sibai, B; Simhan, H; Sonek, J; Werner, E, 2020)
"The use of aspirin for preventing preeclampsia has been practiced recently by fetomaternal specialists in Indonesia."	1.56	Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia. ( Karunia, RI; Prasetyadi, FOH; Purnamayanti, A, 2020)
"In women who developed severe preeclampsia and delivered preterm, there were significant elevations in non-aspirin-sensitive lipids with biologic actions that could cause preeclampsia."	1.56	Placental Production of Eicosanoids and Sphingolipids in Women Who Developed Preeclampsia on Low-Dose Aspirin. ( Al Dulaimi, M; Alam, SMK; Chalfant, CE; Lee, SM; Reep, DT; Springel, EH; Stephenson, DJ; Strauss, JF; Walsh, SW; Washington, SL, 2020)
"Early-onset preeclampsia was found in 3 pregnant women (0."	1.56	Screening for Preeclampsia in the First Trimester and Aspirin Prophylaxis: Our First Year. ( Caeiro, F; Francisco, C; Gomes, H; Lourenço, I; Ribeiro, J; Rocha, P, 2020)
"The benefit of aspirin in preventing preeclampsia is increasingly recognized; however, its mechanism of action remains unclear."	1.56	The 15-Epilipoxin-A4 Pathway with Prophylactic Aspirin in Preventing Preeclampsia: A Longitudinal Cohort Study. ( Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Motum, P; Shanmugalingam, R; Wang, X, 2020)
"In pregnancies with preterm preeclampsia, the mean multiples of the median values of mean arterial pressure and uterine artery pulsatility index were significantly higher (mean arterial pressure, 1."	1.51	Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. ( Chaemsaithong, P; Chaiyasit, N; Choolani, M; Hu, Y; Leung, TY; Leung, WC; Ma, R; Naruse, K; Pooh, RK; Poon, LC; Sahota, D; Saito, S; Sekizawa, A; Seshadri, S; Shaw, SW; Tokunaka, M; Wataganara, T; Wright, A; Yeo, GSH; Zheng, M, 2019)
"The aspirin group was associated with earlier delivery at 38."	1.51	Effect of early use of low-dose aspirin therapy on late-onset preeclampsia. ( Gillin, AG; Hyett, J; Lan, PG; Pelosi, M; Sandager, P; Tooher, J, 2019)
"Aspirin plays an important role in the prevention and therapy of pre-eclampsia."	1.51	Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. ( Ma, Y; Shi, X; Song, L; Yang, S; Zhao, N, 2019)
"Our novel findings suggest that the preeclampsia prevention effect of aspirin may be exerted through these two mechanisms."	1.51	Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. ( Chen, TY; Kuo, PL; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2019)
"Preeclampsia is a hypertensive disorder specific to pregnancy that remains a significant cause of maternal and neonatal morbidity and mortality."	1.48	Low-Dose Aspirin for the Prevention of Preeclampsia. ( Fantasia, HC, 2018)
"Preeclampsia is a severe pregnancy-related disorder, and patients usually present with high circulating inflammatory factor levels and excessive activation of the nuclear factor-κB (NF-κB) pathway."	1.48	The intervention effect of aspirin on a lipopolysaccharide-induced preeclampsia-like mouse model by inhibiting the nuclear factor-κB pathway. ( Li, G; Lin, L; Ma, L; Wang, YL; Yang, H, 2018)
"Aspirin treatment significantly decreased the levels of pro-inflammatory cytokines in serum and placenta tissues of preeclampsia rats."	1.48	Ameliorative effects of aspirin against lipopolysaccharide-induced preeclampsia-like symptoms in rats by inhibiting the pro-inflammatory pathway. ( Liu, F; Lu, X; Sun, J; Tang, D; Zhang, H, 2018)
"Aspirin treatment improves multiple functions of PE-DMSCs."	1.48	Low-dose aspirin treatment enhances the adhesion of preeclamptic decidual mesenchymal stem/stromal cells and reduces their production of pro-inflammatory cytokines. ( Brennecke, SP; Georgiou, HM; Kalionis, B; Khanabdali, R; Murthi, P; Shakouri-Motlagh, A; Wilkinson, S, 2018)
"Presumed rates of preeclampsia were 3."	1.48	Preeclampsia Prevention Using Routine Versus Screening Test-Indicated Aspirin in Low-Risk Women. ( Breathnach, F; Cotter, A; Daly, S; Dicker, P; Higgins, J; Hunter, A; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Morrison, JJ; Mulcahy, C; Normand, C; O'Mahony, JF; Tully, E; Tyrrell, E, 2018)
"The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations."	1.46	Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017)
"The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies."	1.46	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. ( Carbone, IF; de Alvarado, M; Delgado, JL; Dutemeyer, V; Kapeti, E; Nicolaides, KH; Papantoniou, N; Pazos, A; Plasencia, W; Poon, LC; Rehal, A; Rolnik, DL; Syngelaki, A; Vojtassakova, D; Wright, D, 2017)
"Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity."	1.46	Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women? ( Costantine, MM; Marrs, CC, 2017)
"The rate of preeclampsia was much higher at quintile (Q) 5 of VAT depth (9."	1.46	Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy. ( Berger, H; Bujold, E; Connelly, PW; De Souza, LR; Park, AL; Ray, JG, 2017)
"Antiphospholipid syndrome is an autoimmune, hypercoagulable state that is caused by antiphospholipid antibodies."	1.46	Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. ( Berghella, V; Bernabini, D; Dall'Asta, A; Eke, AC; Facchinetti, F; Ghi, T; Hoxha, A; Martinelli, P; Maruotti, GM; Monari, F; Rizzo, G; Rizzo, N; Roman, A; Ruffatti, A; Saccone, G; Sarno, L; Schuit, E; Simonazzi, G; Visentin, S; Xodo, S, 2017)
"Placentas from women with and without preeclampsia were collected."	1.42	Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. ( Li, C; Raikwar, NS; Santillan, DA; Santillan, MK; Thomas, CP, 2015)
"The estimated rate of preeclampsia would be 4."	1.42	A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States. ( Hauspurg, AK; Rouse, DJ; Werner, EF, 2015)
"We noted a 2."	1.42	Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Winn, VD, 2015)
"The residual risk of preeclampsia in high-risk women on aspirin prophylaxis exceeds that of low-risk populations, and this study aimed to identify first-trimester maternal characteristics associated with aspirin prophylaxis failure."	1.40	First-trimester risk factors for preeclampsia development in women initiating aspirin by 16 weeks of gestation. ( Atlas, RO; Baschat, AA; Blitzer, MG; Block-Abraham, DM; Doyle, LE; Jenkins, CB; Kopelman, JN; Turan, OM, 2014)
"(2) Influence of treatment on the pregnancy outcomes and complications: 24 APS patients were given the treatment of aspirin or aspirin combined with low molecular weight heparin, and 30 patients received no treatment."	1.40	[Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study]. ( Deng, XL; Liu, XY; Zheng, XJ, 2014)
"Superimposed preeclampsia occurred in 49 (23."	1.39	Risk factors of superimposed preeclampsia in women with essential chronic hypertension treated before pregnancy. ( Cabrol, D; Goffinet, F; Haddad, B; Lecarpentier, E; Sibai, B; Tsatsaris, V, 2013)
"The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3."	1.38	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012)
"Preterm birth was more frequent in study group than general population (21."	1.38	Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. ( Ahn, H; Beaman, K; Gilman-Sachs, A; Han, AR; Kwak-Kim, J; Park, JC; Vu, P, 2012)
"Treatment with aspirin and LMWH is associated with improved outcomes for women with previous late fetal loss or early delivery due to placental dysfunction (Group 2)."	1.36	Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. ( Bewley, S; Bramham, K; Calatayud, I; Germain, S; Hunt, BJ; Khamashta, M; Nelson-Piercy, C, 2010)
"The occurrence of superimposed preeclampsia should be detected by appropriate clinical and laboratory evaluation."	1.35	[Arterial hypertension in pregnancy]. ( Leeman, M, 2008)
"Diagnosis of polycythemia vera during pregnancy is a very difficult task due to physiologic changes occurring during gestation."	1.32	[Polycythemia vera and pregnancy]. ( Beillat, T; Dreyfus, M; Macro, M, 2004)
"Plasmic 6-keto-PGF1a was low."	1.32	[Endothelium and platelets in pregnant women with chronic glomerulonephritis and therapeutic efficacy of acetylsalicylic acid and dipiridamol]. ( Artem'eva, VB; Gordovskaia, NB; Kozlovskaia, NL; Krylova, MIu; Rogov, VA; Shilov, EM; Sidorova, IS, 2004)
"No patients with preeclampsia or other severe complications of pregnancy were observed in the normalised group."	1.31	Late normalisation of uterine artery velocimetry in high risk pregnancy. ( Danti, L; Frusca, T; Scalvi, L; Soregaroli, M; Valcamonico, A, 2001)
" It is likely that proper selection of patients, as well as the timing and dosage of treatment, are key factors for its efficiency."	1.30	[Arterial hypertension of the pregnant woman]. ( Beaufils, M, 1999)
"Pulmonary edema was rare and acute renal failure did not develop in any women."	1.30	Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. ( Caritis, SN; Dombrowski, MP; Hauth, JC; Hogg, B; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, PJ; Miodovnik, M; Paul, R; Roberts, JM; Sibai, BM; Thurnau, GR; Van Dorsten, JP, 1999)
"To study treatment of hypertension in pregnancy in Sweden and compare our results with a similar study published in 1981."	1.29	How Swedish obstetricians manage hypertensive disorders in pregnancy. A questionnaire study. ( Ingemarsson, I; Montal, S; Wide-Swensson, D, 1994)
"All eight subjects who developed preeclampsia delivered growth-retarded infants before term."	1.29	Increased platelet volume and aggregation precede the onset of preeclampsia. ( Elder, MG; Hutt, R; Ogunniyi, SO; Sullivan, MH, 1994)
"Women on aspirin, who developed preeclampsia, delivered later in pregnancy [35."	1.29	Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. ( Fairley, KF; Ferrier, C; Gamble, G; Kincaid-Smith, P; North, RA, 1995)
"Preeclampsia is a disease which appears only during pregnancy."	1.29	[Physiopathology of preeclampsia]. ( Mejía, R; Sarto, A, 1996)
"Preeclampsia is a hypertensive disorder of human pregnancy that is a leading cause of premature delivery and fetal growth retardation."	1.29	Aspirin inhibits both lipid peroxides and thromboxane in preeclamptic placentas. ( Walsh, SW; Wang, Y, 1995)
"Preeclampsia is associated with an imbalance of increased thromboxane and decreased prostacyclin and an abnormal increase of lipid peroxides."	1.28	Low-dose aspirin inhibits lipid peroxides and thromboxane but not prostacyclin in pregnant women. ( Kay, HH; McCoy, MC; Walsh, SW; Wang, Y, 1992)
"Preeclampsia is characterized by imbalances in the production rates of several arachidonic acid metabolites."	1.27	The role of arachidonic acid metabolites in preeclampsia. ( Parisi, VM; Walsh, SW, 1986)
"In patients with preeclampsia the renal excretion of beta 2-microglobulin allows to differentiate between a primary preeclampsia and a preeclampsia superimposed upon chronic pyelonephritis."	1.26	Beta 2-microglobulin and other proteins as parameter for tubular function. ( Jaques, G; Keller, M; Mondorf, AW; Prüfer, D; Weise, M, 1981)

Research

Studies (783)

Authors

Clinical Trials (59)

Trial Overview

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

Fetal Outcome 4 - Incidence of Fetal Loss

Fetal Outcome 5 - Incidence of Spontaneous Abortion

Fetal Outcome 6 - Incidence of All Stillbirth

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

Timeframe	Studies, this research(%)	All Research%
pre-1990	27 (3.45)	18.7374
1990's	164 (20.95)	18.2507
2000's	98 (12.52)	29.6817
2010's	249 (31.80)	24.3611
2020's	245 (31.29)	2.80

Authors	Studies
Davidson, KW	1
Barry, MJ	1
Mangione, CM	1
Cabana, M	1
Caughey, AB	3
Davis, EM	1
Donahue, KE	1
Doubeni, CA	1
Kubik, M	1
Li, L	4
Ogedegbe, G	1
Pbert, L	1
Silverstein, M	1
Simon, MA	1
Stevermer, J	1
Tseng, CW	1
Wong, JB	1
Henderson, JT	3
Vesco, KK	1
Senger, CA	2
Thomas, RG	1
Redmond, N	1
Jin, J	1
Espinoza, J	1
Giorgione, V	2
Di Fabrizio, C	1
Thilaganathan, B	6
Anthoulakis, C	1
Mamopoulos, A	1
Rousso, D	1
Karagiannis, A	1
Athanasiadis, A	1
Grimbizis, G	1
Athyros, V	1
Shrestha Khatri, N	1
White, SW	1
Graham, DF	1
Krishnamurti, T	1
Davis, AL	1
Rodriguez, S	1
Hayani, L	1
Bernard, M	1
Simhan, HN	2
Lewkowitz, AK	1
Rouse, DJ	4
Ye, Y	1
Wen, L	1
Liu, X	2
Wang, L	1
Liu, Y	1
Saffery, R	1
Kilby, MD	1
Tong, C	1
Qi, H	3
Baker, P	1
Zen, M	1
Haider, R	1
Simmons, D	1
Peek, M	1
Nolan, CJ	1
Padmanabhan, S	2
Jesudason, S	1
Alahakoon, TI	1
Cheung, NW	2
Lee, VW	1
Landman, AJEMC	1
van Limburg Stirum, EVJ	1
de Boer, MA	1
van 't Hooft, J	1
Ket, JCF	1
Leemhuis, AG	1
Finken, MJJ	1
Oudijk, MA	2
Painter, RC	1
Gulersen, M	1
Rochelson, B	1
Hantoushzadeh, S	2
Saleh, M	1
Nouri, B	1
Panahi, Z	1
Combs, CA	6
Zhou, MK	4
Pandipati, S	4
Rosario, AD	1
Ju, Y	2
Feng, Y	2
Hou, X	2
Wu, L	1
Yang, H	9
Zhang, H	4
Ma, Y	3
Jayaram, A	1
Buhimschi, IA	1
Buhimschi, CS	1
Wheeler, SM	1
Myers, SO	1
Swamy, GK	1
Myers, ER	1
Reis de Carvalho, C	1
Bigotte Vieira, M	1
Costa, J	1
Vaz Carneiro, A	1
Yip, KC	1
Luo, Z	1
Huang, X	2
Lee, W	1
Dai, C	1
Zeng, W	1
Mok, TN	1
He, Q	1
Li, R	1
Wright, D	11
Tan, MY	4
O'Gorman, N	7
Syngelaki, A	12
Nicolaides, KH	24
Perni, UC	1
Wang, EY	1
Gregg, AR	1
Mkhize, PZ	1
Phoswa, WN	1
Khaliq, OP	1
Dorsamy, V	1
Moodley, J	1
Ray, JG	8
Abdulaziz, KE	1
Berger, H	3
Hodgetts Morton, V	2
Stock, SJ	1
Vallejo, GM	1
Uriel, M	1
Porras-Ramírez, A	1
Romero, XC	1
Sole, KB	1
Staff, AC	1
Räisänen, S	1
Laine, K	1
Theilen, LH	1
Greenland, P	1
Varagic, J	1
Catov, J	1
Shanks, A	1
Thorsten, V	1
Parker, CB	1
McNeil, R	1
Mercer, B	1
Hoffman, M	1
Wapner, R	1
Haas, D	1
Simhan, H	2
Grobman, W	3
Chung, JH	1
Levine, LD	1
Barnes, S	1
Bairey Merz, N	1
Saade, G	4
Silver, RM	5
Wright, A	3
Walsh, SW	12
Strauss, JF	5
Bijl, RC	1
Cornette, JMJ	1
Brewer, AN	1
Zwart, IF	1
Franx, A	1
Tsigas, EZ	1
Koster, MPH	1
Deng, Z	1
Wang, X	6
Lu, D	2
Hastie, R	3
Tong, S	5
Wikström, AK	2
Walker, SP	2
Lindquist, A	1
Cluver, CA	2
Kupka, E	2
Bergman, L	2
Hesselman, S	2
Zhang, J	9
Jing, S	2
Xie, H	2
Feng, L	2
Ortiz-Basso, T	1
Gomez, PV	1
Boffelli, A	1
Paladini, A	1
Espeche, WG	1
Minetto, J	1
Salazar, MR	1
Delgado, A	1
Katz, L	1
Amorim, MM	1
Mirabito Colafella, KM	2
van Dorst, DCH	1
Neuman, RI	2
Doorn, LV	1
Neves, KB	1
Montezano, AC	1
Garrelds, IM	1
van Veghel, R	1
de Vries, R	1
Uijl, E	1
Clahsen-van Groningen, MC	1
Baelde, HJ	1
van den Meiracker, AH	1
Touyz, RM	1
Visser, W	3
Danser, AHJ	2
Versmissen, J	2
Leeson, C	1
Odendaal, J	1
Quenby, S	1
Francisco, C	2
Gamito, M	1
Reddy, M	2
Rolnik, DL	16
Chen, D	3
Yang, S	3
Ding, J	2
Liu, A	1
Olson, DN	1
Russell, T	1
Ranzini, AC	1
Kasraeian, M	3
Asadi, N	3
Vafaei, H	3
Tazang, M	2
Rahimirad, N	2
Yousofi, S	2
Khaleghi, SF	2
Zare, M	3
Akalin, EE	1
Akalin, M	1
Ayvaci Tasan, H	1
Koyuncu, K	1
Murphy, L	1
Saldanha, IJ	1
Sawyer, K	1
Gupta, M	1
Mendez-Figueroa, H	4
Burwick, R	1
Chauhan, SP	1
Wagner, SM	1
Ukoha, EP	1
Snavely, ME	1
Hahn, MU	1
Steinauer, JE	1
Bryant, AS	1
Tani, C	1
Zucchi, D	1
Haase, I	1
Gerosa, M	1
Larosa, M	1
Cavagna, L	1
Bortoluzzi, A	1
Crisafulli, F	1
Mucke, J	1
Strigini, FAL	1
Baglietto, L	1
Fornili, M	1
Monacci, F	1
Elefante, E	1
Erra, R	1
Bellis, E	1
Padovan, M	1
Andreoli, L	2
Coletto, LA	1
Zanframundo, G	1
Govoni, M	1
Iaccarino, L	1
Tincani, A	2
Doria, A	2
Fischer-Betz, R	2
Mosca, M	2
Suksai, M	1
Geater, A	1
Suntharasaj, T	1
Suwanrath, C	1
Charernjiratragul, K	1
Khwankaew, N	1
Andrade, JA	1
Viana Junior, AB	1
Holanda Moura, SB	1
Gurgel Alves, JA	1
Araujo Júnior, E	1
Carvalho, FH	1
de Jong, MFC	1
Komdeur, HM	1
Salih, M	1
Meijer, E	1
Guo, Y	2
Zhu, Y	6
Sun, Y	1
Tomimori-Gi, K	1
Katsuragi, S	1
Kodama, Y	1
Yamada, N	1
Sameshima, H	1
Maekawa, K	1
Yamashita, A	1
Gi, T	1
Sato, Y	1
Romagano, MP	2
Sherman, LS	2
Shadpoor, B	1
El-Far, M	1
Souayah, S	1
Pamarthi, SH	1
Kra, J	1
Hood-Nehra, A	1
Etchegaray, JP	2
Williams, SF	2
Rameshwar, P	2
Foisy, MA	3
Kingdom, JC	4
Bujold, E	32
Ogoyama, M	1
Takahashi, H	1
Suzuki, H	1
Ohkuchi, A	1
Fujiwara, H	1
Takizawa, T	1
Fantasia, I	1
Bussolaro, S	1
Stampalija, T	1
Ninan, K	1
Ali, R	1
Morfaw, F	1
McDonald, SD	1
Zhang, Y	4
Song, L	2
Pathiraja, PDM	1
Alrub, NA	1
Sunanda, G	1
Richards, EMF	2
Stevens, O	1
Diguisto, C	1
Le Gouge, A	1
Marchand, MS	1
Megier, P	1
Ville, Y	1
Haddad, G	1
Winer, N	3
Arthuis, C	1
Doret, M	1
Debarge, VH	1
Flandrin, A	1
Delmas, HL	1
Gallot, D	1
Mares, P	2
Vayssiere, C	2
Sentilhes, L	4
Cheve, MT	1
Paumier, A	1
Durin, L	1
Schaub, B	1
Equy, V	1
Giraudeau, B	1
Perrotin, F	1
Liu, YH	1
Zhang, YS	1
Chen, JY	1
Wang, ZJ	1
Liu, YX	1
Li, JQ	1
Xu, XJ	1
Xie, NJ	1
Lye, S	1
Tan, N	1
Duan, CY	1
Wei, YX	1
He, PC	1
Yang, Y	1
Zhang, X	1
Zhu, X	2
Wang, Y	5
Yang, M	1
Phelps, AJD	1
Holmgren, C	1
Kawaguchi, H	1
Kanagawa, T	1
Yamamoto, R	1
Sasahara, J	1
Okamoto, Y	1
Mitsuda, N	2
Ishii, K	2
Ghesquiere, L	3
Vachon-Marceau, C	1
Ferreira, E	3
Côté, S	4
Guerby, P	6
Maheux-Lacroix, S	1
Xiao, S	1
Guo, L	1
Zhang, M	3
Hu, R	1
Liu, R	1
Marchant, I	2
Lessard, L	1
Caron, L	1
Al Dulaimi, M	2
Ngwira, MM	3
Gadama, LA	3
Shanmugalingam, R	10
Makris, A	10
Hennessy, A	10
Johnson, JM	3
Walsh, JD	3
Okun, NB	3
Metcalfe, A	4
Pastuck, ML	3
Maxey, CM	3
Soliman, N	3
Mahallati, H	3
Kuret, VH	3
Dwinnell, SJ	3
Chada, R	3
O'Quinn, CP	3
Schacher, J	3
Somerset, DA	3
Paterson, K	3
Suchet, IB	3
Silang, KA	3
Paul, H	3
Nerenberg, KA	3
Johnson, DW	3
D'Antonio, F	4
Khalil, A	7
Rizzo, G	5
Fichera, A	3
Herrera, M	3
Buca, D	3
Morelli, R	3
Cerra, C	3
Orabona, R	3
Acuti Martellucci, C	3
Flacco, ME	3
Prefumo, F	4
Phillips, J	3
Nathan, E	3
Graham, D	3
Ye, YZ	3
Zhou, QJ	3
Xiao, XR	3
Xiong, Y	3
Li, XT	3
Ansbacher-Feldman, Z	3
Meiri, H	6
Cirkin, R	3
Louzoun, Y	3
Del Rosario, A	3
Danjuma, MI	2
Al-Khulaifi, A	2
Elshafei, MN	2
Pyeon, SY	1
Kwon, BS	1
Kim, YS	1
Lee, YJ	1
Singh, S	1
Misra, S	1
Di Girolamo, R	1
Alameddine, S	1
Santilli, F	1
Maruotti, GM	2
Liberati, M	1
Xiao, Y	1
Ling, Q	1
Yao, M	1
Gu, Y	2
Lan, Y	1
Liu, S	1
Yin, J	1
Ma, Q	1
Magee, LA	6
von Dadelszen, P	7
Dimitriadis, E	1
Zhou, W	1
Estrada-Gutierrez, G	1
Koga, K	1
Francisco, RPV	1
Whitehead, C	1
Hyett, J	9
da Silva Costa, F	6
Nicolaides, K	6
Menkhorst, E	1
Mendoza, M	3
Bonacina, E	1
Garcia-Manau, P	1
López, M	1
Caamiña, S	1
Vives, À	1
Lopez-Quesada, E	1
Ricart, M	2
Maroto, A	1
de Mingo, L	1
Pintado, E	1
Ferrer-Costa, R	1
Martin, L	1
Rodríguez-Zurita, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940]		640 participants (Anticipated)	Interventional	2023-06-19	Not yet recruiting
Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial[NCT06108947]		300 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523]		3,000 participants (Anticipated)	Interventional	2023-07-03	Recruiting
162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164]	Phase 4	200 participants (Anticipated)	Interventional	2021-07-06	Recruiting
Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial[NCT00986765]	Phase 3	257 participants (Actual)	Interventional	2009-06-30	Completed
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167]	Phase 4	2,500 participants (Anticipated)	Interventional	2023-11-06	Recruiting
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]		11,976 participants (Actual)	Interventional	2016-03-23	Completed
Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia[NCT04797949]	Phase 4	156 participants (Anticipated)	Interventional	2021-03-03	Recruiting
Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome[NCT02303171]	Phase 4	100 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS[NCT00180778]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2005-10-31	Not yet recruiting
Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778]	Phase 2	60 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss[NCT00564174]		88 participants (Actual)	Interventional	2000-03-31	Terminated (stopped due to interim analysis found no difference in LB rate and lower than expected event rate)
A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin Versus Low-molecular-weight Heparin (LMWH) and Aspirin in Women With Antiphospholipid Syndrome and Pregnancy Loss[NCT03100123]	Early Phase 1	1 participants (Actual)	Interventional	2017-11-06	Terminated (stopped due to Pilot deemed not feasible by Steering Committee due to recruitment rate.)
Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother[NCT00959621]	Phase 3	220 participants (Actual)	Interventional	2002-01-31	Completed
The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363]		1,228 participants (Actual)	Interventional	2007-06-30	Completed
Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin[NCT02144064]	Phase 3	200 participants (Anticipated)	Interventional	2019-06-23	Recruiting
A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)[NCT01661439]		316 participants (Anticipated)	Observational	2012-03-31	Recruiting
PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy[NCT06115122]		3,000 participants (Anticipated)	Observational [Patient Registry]	2022-02-15	Recruiting
Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol[NCT05709483]	Early Phase 1	130 participants (Anticipated)	Interventional	2023-04-13	Recruiting
Preeclampsia Intervention 4 - A Triple Blind Phase III Randomised Controlled Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia[NCT06033131]	Phase 3	294 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.[NCT02797249]	Phase 3	1,000 participants (Actual)	Interventional	2016-12-07	Completed
Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial[NCT03871491]	Phase 3	34,000 participants (Anticipated)	Interventional	2020-09-01	Active, not recruiting
A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573]	Phase 3	400 participants (Anticipated)	Interventional	2019-10-21	Enrolling by invitation
Role of Aspirin in Maternal Endothelial Dysfunction and Uterine Artery Blood Flow in Women at Risk for Preeclampsia[NCT03893630]	Phase 2	250 participants (Anticipated)	Interventional	2019-04-25	Recruiting
IMPACT - Study for Improving Maternal, Pregnancy and Child Outcomes[NCT03831490]		13,000 participants (Actual)	Observational [Patient Registry]	2018-11-09	Active, not recruiting
First-trimester Placental Ultrasound Study (First PLUS): an Observational Cohort Study to Assess the Clinical Utility of the OxNNet Toolkit for the Prediction of Adverse Pregnancy Outcomes.[NCT05326191]		4,000 participants (Actual)	Observational	2022-03-15	Completed
The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population[NCT05089175]		4,500 participants (Anticipated)	Observational [Patient Registry]	2021-11-30	Recruiting
A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy[NCT04158830]	Phase 4	0 participants (Actual)	Interventional	2020-06-01	Withdrawn (stopped due to PI is no longer at this University.)
STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)[NCT04767438]		6,560 participants (Anticipated)	Observational	2021-03-31	Not yet recruiting
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982]	Phase 4	60 participants (Anticipated)	Interventional	2021-05-28	Recruiting
Implementation of First-trimester Screening and Prevention of Preeclampsia: a Stepped Wedge Cluster-randomized Trial in Asia[NCT03941886]		42,454 participants (Actual)	Interventional	2019-07-31	Completed
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781]	Phase 3	476 participants (Anticipated)	Interventional	2020-07-01	Recruiting
Fetal Growth and Placental Function in Pregnancies Complicated by Diabetes[NCT04801121]		100 participants (Anticipated)	Observational [Patient Registry]	2020-11-01	Enrolling by invitation
First-trimester Preeclampsia Screening: Women's Perspectives[NCT05123560]		750 participants (Anticipated)	Observational	2022-04-01	Not yet recruiting
Fetal, Obstetrics and Reproduction Genomics[NCT05720169]		400 participants (Anticipated)	Observational	2023-10-01	Not yet recruiting
A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort[NCT04631627]	Phase 4	1,500 participants (Anticipated)	Interventional	2020-11-16	Not yet recruiting
Acetylsalicylic Acid for Postpartum Preeclampsia: A Pilot Randomized Trial[NCT05924971]	Phase 2	86 participants (Anticipated)	Interventional	2023-07-26	Recruiting
Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799]	Phase 4	150 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients[NCT03648970]	Phase 2	280 participants (Anticipated)	Interventional	2018-03-01	Recruiting
Early Prediction and Aspirin for Prevention of Preeclampsia[NCT01547390]		104 participants (Actual)	Interventional	2012-03-31	Terminated (stopped due to Terminated after Aspirin was recommended by the USPTF to Prevent Preeclampsia.)
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)[NCT00198068]		700 participants (Anticipated)	Observational	2003-09-30	Recruiting
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513]		414 participants (Anticipated)	Interventional	2022-03-24	Not yet recruiting
Assessment of the Cardiovascular Risk Profile of Infants Exposed to Pre-eclampsia in Utero[NCT05091827]		234 participants (Anticipated)	Observational	2021-11-30	Not yet recruiting
An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction[NCT03674606]	Phase 4	546 participants (Actual)	Interventional	2014-02-01	Completed
Efficacy L-arginine + L-citrulline as a Dietary Supplement vs Placebo for Weight Gain in Fetus With a Decrease in Their Growth Curve in the Third Trimester of Pregnancy[NCT05029778]	Phase 4	41 participants (Anticipated)	Interventional	2021-10-20	Not yet recruiting
Prospective Validation of Prediction Algorithms for Preeclampsia in the First-trimester of Pregnancy[NCT03554681]		10,935 participants (Actual)	Observational	2016-12-31	Completed
Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.[NCT02174328]	Phase 3	81 participants (Actual)	Interventional	2014-05-21	Terminated (stopped due to Halted prematurely due to low recruitment rate.)
The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study[NCT00683202]		374 participants (Actual)	Interventional	2001-03-31	Completed
Association Between Preeclampsia, Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure, Systemic Arterial Pressure and Cardiovascular Function.[NCT05679206]		900 participants (Anticipated)	Observational	2022-12-20	Recruiting
Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome[NCT04275778]	Phase 2	110 participants (Anticipated)	Interventional	2021-07-09	Recruiting
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2016-09-15	Recruiting
Diagnostic Value of microRNA 210 In Preeclampsia[NCT03193554]		80 participants (Anticipated)	Observational [Patient Registry]	2019-01-01	Recruiting
Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers[NCT01729468]	Phase 4	1,106 participants (Actual)	Interventional	2012-06-27	Completed
A Multi-center, Double-Blind Randomized, Cross-over, Active-control, Comparative Clinical Study to Evaluate the Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-Controlled Hypertensive Patients (Phase IV)[NCT00386529]	Phase 4	191 participants (Actual)	Interventional	2006-09-30	Completed
Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial[NCT02754635]		320 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649]	Phase 4	62 participants (Actual)	Interventional	2020-02-10	Completed
Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls[NCT03151330]		2,110 participants (Anticipated)	Interventional	2018-06-15	Active, not recruiting
A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278]		0 participants (Actual)	Observational	2008-08-31	Withdrawn (stopped due to No participants)
A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500]	Phase 4	24 participants (Actual)	Interventional	2003-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Intervention Arm	189
Placebo Arm	230

Intervention	Participants (Count of Participants)
Intervention Arm	1078
Placebo Arm	1153

Intervention	Participants (Count of Participants)
Intervention Arm	78
Placebo Arm	101

Intervention	Participants (Count of Participants)
Intervention Arm	303
Placebo Arm	353

Intervention	Participants (Count of Participants)
Intervention Arm	134
Placebo Arm	152

Intervention	Participants (Count of Participants)
Intervention Arm	141
Placebo Arm	166

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

Incidence of Hypertensive Disorders of Pregnancy

Intervention	Participants (Count of Participants)
Intervention Arm	42
Placebo Arm	30

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

Incidence of Perinatal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	352
Placebo Arm	325

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Incidence of Preterm Birth

Intervention	Participants (Count of Participants)
Intervention Arm	264
Placebo Arm	309

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

Incidence of Small for Gestational Age (SGA)

Intervention	Participants (Count of Participants)
Intervention Arm	668
Placebo Arm	754

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 1 - Incidence of Vaginal Bleeding

Intervention	Participants (Count of Participants)
Intervention Arm	1506
Placebo Arm	1564

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	214
Placebo Arm	246

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	26
Placebo Arm	25

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 4 - Incidence of Maternal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	54
Placebo Arm	43

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 5 - Incidence of Late Abortion

Intervention	Participants (Count of Participants)
Intervention Arm	9
Placebo Arm	12

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 6 - Change in Maternal Hemoglobin

Intervention	Participants (Count of Participants)
Intervention Arm	23
Placebo Arm	30

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Intervention	Participants (Count of Participants)
Intervention Arm	290
Placebo Arm	333

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

Intervention	Participants (Count of Participants)
Intervention Arm	8
Placebo Arm	21

Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation

Consent

Intervention	Percentage of pregnancies (Number)
Enoxaparin 40 mg /Day Plus Low Dose Aspirin	24
Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin	20

Proportion of eligible subjects who provide consent. (NCT03100123)
Timeframe: 24 months

Crossover Rate

Intervention	Participants (Count of Participants)
Consented Eligible Patients	1

Crossover rate between standard of care and experimental study arms. (NCT03100123)
Timeframe: 52 weeks

Eligibility

Intervention	Participants (Count of Participants)
Crossover Rate	0

Proportion of screened patients who meet eligibility criteria (i.e. patients who meet inclusion criteria and are also eligible based on exclusion criteria). (NCT03100123)
Timeframe: 24 months

Essential Documents

Intervention	Participants (Count of Participants)
Screened Patients Who Met Eligibility Criteria	4

Proportion of sites requiring >18 months to obtain all required approvals/contracts from time of delivery of all study documents. (NCT03100123)
Timeframe: 18 months

Study Drug Compliance

Intervention	Sites (Number)
Approval Timeline	1

Level of compliance with study drug through patient recall and patient medication diary. (NCT03100123)
Timeframe: 52 weeks

Study Feasibility: Mean Recruitment Rate Per Center Per Month

Intervention	Participants (Count of Participants)
Standard of Care Arm	0
Experimental Arm	1

The primary feasibility outcome of the pilot trial is the mean recruitment rate per center per month. (NCT03100123)
Timeframe: 24 months

Withdrawals/Loss to Follow-up

Intervention	participants (Number)
Experimental Arm	1

Proportion of withdrawals/loss to follow-up among randomized patients. (NCT03100123)
Timeframe: 24 months

Abruption

Intervention	Participants (Count of Participants)
Withdrawal/Lost to Follow-up	0

Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery

Clinically Recognized Pregnancy

Early Pregnancy Loss (EPL)

Ectopic Pregnancy

Fetal Pregnancy Loss

hCG Recognized Pregnancy

Live Birth

Intervention	participants (Number)
Aspirin	7
Placebo	5

Intervention	pregnancy (Number)
Aspirin	374
Placebo	346

Intervention	pregnancy (Number)
Aspirin	28
Placebo	27

Intervention	pregnancy (Number)
Aspirin	3
Placebo	3

Intervention	pregnancy (Number)
Aspirin	4
Placebo	6

Intervention	pregnancy (Number)
Aspirin	394
Placebo	363

Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery

Molar Pregnancy

Preeclampsia

Pregnancy Losses Occurring Less Than 10 Weeks

Intervention	livebirths (Number)
Aspirin	309
Placebo	286

Intervention	pregnancy (Number)
Aspirin	0
Placebo	0

Intervention	participants (Number)
Aspirin	32
Placebo	30

Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks

Preterm Birth

Small for Gestational Age Infant

Stillbirth

Number of Participants With Preeclampsia

Intervention	pregnancy (Number)
Aspirin	56
Placebo	53

Intervention	infants (Number)
Aspirin	22
Placebo	31

Intervention	grams (Mean)
Aspirin	3327
Placebo	3315

Intervention	participants (Number)
Aspirin	2
Placebo	2

Preeclampsia diagnosed per ACOG criteria: Blood pressure greater than 140/90 on 2 occasions 6 hrs apart and significant proteinuria (greater than 300mg in 24hrs). (NCT01547390)
Timeframe: within 3 months prior to delivery

Number of Participants With IUGR, Early Preeclampsia, Severe Preeclampsia, Gestational Hypertension, Preterm Birth, Stillbirth, Placental Abruption, Antepartum Hemorrhage, Neonatal Death, NICU Admission, Miscarriage

Intervention	Participants (Count of Participants)
Placebo	3
Aspirin	3

"Intrauterine growth restriction (IUGR) - estimated fetal weight less than 10th percentile early preeclampsia - preeclampsia delivered prior to 34 weeks severe preeclampsia - blood pressure greater then 160/110 gestational hypertension - hypertension without features of preeclampsia preterm birth, stillbirth, placental abruption, antepartum hemorrhage, neonatal death, NICU admission, miscarriage.~Statistical significance not reported due to the low recruitment and poor patient compliance." (NCT01547390)
Timeframe: within 3 months of delivery

Duration of Headache Free Period at 7 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 28 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 7 Days

Number of Participants With Injection Site Complication (Infection, Hematoma, and Ecchymosis)

Number of Participants With Need for Admission for Treatment of Headache

Number of Participants With Need for Crossover Treatment

Number of Participants With Need for Neurology Consult

Number of Participants With Need for Representation for Treatment of Headache With 28 Days

Intervention	participants (Number)
	Small for gestational age (IUGR)	Gestational hypertension	Early preeclampsia	Severe preeclampsia	Preterm birth	Stillbirth	Placental abruption	antepartum hemorrhage	neonatal death	NICU admission	miscarriage
Aspirin	1	2	1	3	1	0	0	0	0	2	0
Placebo	1	0	1	3	2	0	0	0	0	0	1

Intervention	days (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	1

Intervention	Participants (Count of Participants)
Occipital Nerve Block	9
Oral Acetaminophen/Caffeine Group	4

Intervention	Participants (Count of Participants)
Occipital Nerve Block	7
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	0

Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days

Number of Participants With Need for Second Line Treatment

Number of Participants With Response to Occipital Nerve Block in Pregnancy

Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min

Response to Cross Over Treatment at 60 Min

"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min

Response to Second Line Treatment at 60 Min

Response to Treatment Within 2 Hours

Reviews

Trials

Other Studies

413 other studies available for aspirin and Edema-Proteinuria-Hypertension Gestosis